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Chronic myeloid leukemia (CML) is a malignant clonal blood disease that originates from
a pluripotent hematopoietic stem cell. The cytogenetic hallmark of CML, the Philadelphia
chromosome (Ph), is formed as a result of reciprocal translocation between chromosomes
9 and 22, which leads to a formation of a chimeric BCR-ABL fusion gene. The BCR-ABL
protein  is  a  constitutively  active  tyrosine  kinase  that  changes  the  adhesion  properties  of
cells, constitutively activates mitogenic signaling, enhances cell proliferation and reduces
apoptosis. This results in leukemic growth and the clinical disease, CML. With the advent
of targeted therapies against the BCR-ABL fusion protein, the treatment of CML has
changed considerably during the recent decade. In this thesis, the clinical significance of
different diagnostic methods and new prognostic factors in CML have been assessed.
First, the association between two different methods for measuring CML disease
burden (the RQ-PCR and the high mitotic index metaphase FISH) was assessed in bone
marrow and peripheral blood samples. The correlation between positive RQ-PCR and
metaphase FISH samples was high. However, RQ-PCR was more sensitive and yielded
measurable transcripts in 40% of the samples that were negative by metaphase FISH. The
study established a laboratory-specific conversion factor for setting up the International
Scale when standardizing RQ-PCR measurements.
Secondly, the amount of minimal residual disease (MRD) after allogeneic
hematopoietic stem cell transplantation (alloHSCT) was determined. For this, metaphase
FISH was done for the bone marrow samples of 102 CML patients. Most (68%), had no
residual cells during the entire follow-up time. Some (12 %) patients had minor (<1%)
MRD which decreased even further with time, whereas 19% had a progressive rise in
MRD that exceeded 1% or had more than 1% residual cells when first detected. Residual
cells did not become eradicated spontaneously if the frequency of Ph+ cells exceeded 1%
during follow-up. The practical value of this 1% MRD level after alloHSCT and the
usefulness of metaphase FISH analytics were examined.
Next, the impact of deletions in the derivative chromosome 9, a putative poor
prognosis marker, was examined. Deletions were observed in 15% of the CML patients
who later received alloHSCT. After alloHSCT, there was no difference in the total relapse
rate  in  patients  with  or  without  deletions.  Nor  did  the  estimates  of  overall  survival,
transplant-related mortality, leukemia-free survival and relapse-free time show any
difference between these groups. When conventional treatment regimens are used, the
der(9) status could be an important criterion, in conjunction with other prognostic factors,
when allogeneic transplantation is considered. The significance of der(9) deletions for
patients treated with tyrosine kinase inhibitors is not clear and requires further
investigation.
In addition to the der(9) status of the patient, the significance of bone marrow
lymphocytosis as a prognostic factor in CML was assessed. Bone marrow lymphocytosis
during imatinib therapy was a positive predictive factor and heralded optimal response.
When  combined  with  major  cytogenetic  response  at  three  months  of  treatment,  bone
8marrow lymphocytosis predicted a prognostically important major molecular response at
18 months of imatinib treatment. Although the validation of these findings is warranted,
the determination of the bone marrow lymphocyte count could be included in the
evaluation of early response to imatinib treatment already now.
Finally, BCR-ABL kinase domain mutations were studied in CML patients resistant
against imatinib treatment. Point mutations detected in the kinase domain were the same
as previously reported, but other sequence variants, e.g. deletions or exon splicing, were
also found. The clinical significance of the other variations remains to be determined.
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Leukemia is a malignant blood cell disease characterized by uncontrolled cell
proliferation, by reduced apoptosis and, in certain types of leukemia, also by insufficient
differentiation that leads to displacement of normal blood cells and accumulation of
malignant cells into the bone marrow and in the peripheral blood. Leukemias are divided
into acute and chronic and into myeloid and lymphatic forms, depending on the stage of
maturation and the hematopoietic cell lineage that is pathological.
Cancer is a genetic disease in the sense that the tumor cells become malignant after
accumulation of various genetic changes which give the cell a growth advantage over
normal cells; this leads to clonal proliferation. These acquired genetic aberrations occur at
the chromosomal level and they result in numerical and structural changes of the normal
chromosome complement, or, on the molecular level, cause mutations in genes that
control cell proliferation and differentiation.
The chromosomal changes of leukemias are nonrandom, i.e., specific abnormalities are
often observed in certain types of leukemias and have therefore diagnostic significance.
Certain abnormalities also have prognostic significance. Some aberrations are also a
prerequisite for targeted therapies. A good example of this is the translocation
t(9;22)(q34;q11.2) which is necessary for successful imatinib treatment. The clonal
aberration detected during the diagnostic workup may later be used as a leukemia-specific
marker when the response to the given treatment is evaluated.
The  story  of  chronic  myeloid  leukemia  (CML)  is  a  classical  example  of  how
discoveries in the field of cancer genetics may eventually provide targeted tools for the
treatment of malignant diseases. The story begins with the initial observation of a
consistent chromosomal abnormality in CML patients. This was followed by the
identification of a chromosomal translocation that was the cause for this aberration. This
lead to molecular cloning of the genes involved in the translocation, characterization of a
leukemogenic fusion gene and protein, and, finally, to a small molecule inhibitor targeted
to inhibit that protein. This story has continued to other cancer types, and hopefully many
others  will  follow.  In  CML the  process  from a  recurrent  chromosomal  abnormality  to  a
targeted drug took nearly 40 years, but the current use of high-throughput technologies
will hopefully ensure more rapid drug development.
In this study, the significance of novel prognostic factors in the treatment of CML was
assessed at a time when tyrosine kinase inhibitors became widely available for clinical
use. The study focused on the technical and clinical applications of methods used to detect
minimal  residual  disease  and  on  determining  the  impact  of  other  aberrations  on  the
outcome of patients after allogeneic hematopoietic stem cell transplantation. The factors
that influence the variable response to imatinib treatment were also evaluated.
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Review of the literature
1. History of CML
The first patients with CML were reported separately by John Bennett and soon after him
by Rudolf Virchow in 1845. Bennett’s mentor David Craigie also had observed a patient
with unusual blood consistency and a splenic tumor already in 1841 but the case was not
reported until a second case with similar features was presented. Bennett and Virchow
both described a patient who had enlarged spleen and liver and whose blood veins were
full of “material resembling thick pus”. Bennett’s conclusion for the cause of death of his
patient was therefore “suppuration of the blood”. Since techniques for staining blood were
not  available  in  those  days,  microscopic  observations  were  rather  crude,  but  both
researches described white or “colorless” cells that had nuclei of either granular or various
shape. Virchow used the term “Weißes Blut” to describe his observation and actually
proposed the word “Leukämie” for delineating the condition, whereas “leucocythemia”
was Bennett’s term for the disease. The attempts to classify different types of leukemia
included Virchow’s division of splenic and lymphatic types, referring to myeloid and
lymphatic leukemia, respectively. The classification of myeloid and lymphatic leukemia
was made by Paul Ehrlich in 1887, who also supported the idea of common stem cell
origin of the different blood cell lineages (reviewed by Geary, 2000 and Tefferi 2008) 1-2.
The concept of myeloproliferative disorders - consisting of diseases like polycythemia
vera, essential thrombocytosis, primary myelofibrosis and chronic myeloid leukemia - was
introduced by William Dameshek in 1951. He defined these diseases as having similar
features and “proliferative activity of the bone marrow cells, perhaps due to a hitherto
undiscovered stimulus” 3.
The cytogenetic hallmark of CML, the Philadelphia chromosome (Ph), is the first
consistent chromosomal abnormality that has been associated to a certain cancer type. The
Ph chromosome was first reported by Peter Nowell and David Hungerford in the
University of Pennsylvania in Philadelphia, United States after studying peripheral blood
samples of patients with leukemia, including two CML patients (Figure 1). The minute Ph
chromosome was first interpreted as being a deleted or otherwise aberrant Y chromosome
since the first studied CML patients were both men 4.  Later  the  size  of  the  patient
population studied grew larger and the Ph chromosome was considered as deriving from
the smallest autosome (other than sex chromosome), namely chromosome 21 5-6.
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Figure 1 The cytogenetic hallmark of CML. Original findings from the article of Nowell and
Hungerford describing a minute Ph chromosome in a metaphase cell of a CML
patient. The Ph chromosome is indicated with an arrow. Reprinted by permission
from Oxford University Press, J. Natl. Cancer Inst. ref. 4, copyright 1960.
The variability in describing the chromosomal origin of the Ph chromosome was mainly
due to lack of chromosome banding methods, first of which were developed in the late
1960’s 7-8.  Soon  after  this  invention  the  Ph  was  identified  as  a  chromosome  22  with  a
deletion in the long arm 9. Since banding methods made possible to distinguish each
chromosome pair from each other and determining the structure of normal chromosomes
by their unique banding patterns, the origin of the Ph chromosome was finally discovered
as a reciprocal (two-way) translocation between the long arms of chromosomes 9 and 22.
This translocation creates an elongated derivative chromosome 9 and a shortened
derivative chromosome 22, the latter of which is the Ph chromosome 10. High resolution
cytogenetic analyses refined the exact breakpoints to subbands 9q34.1 and 22q11.2, so the
translocation is marked as t(9;22)(q34.1;q11.2) 11.
The molecular pathology of t(9;22)(q34;q11.2) rearrangement was identified in the
1980’s. The c-ABL (ABL, ABL1), the human cellular homologue of the transforming
sequence of Abelson murine leukemia virus (A-MuLV) previously mapped to
chromosomal region 9q34, was found to be translocated to the Ph chromosome using
somatic cell hybrid assays 12-13. This finding confirmed the reciprocal nature of the 9;22
translocation and suggested the role of c-ABL in  the  pathogenesis  of  CML 13-14. The
translocation breakpoints in chromosome 22 were observed to be clustered within a region
of  5.8  kb  that  was  termed  the  “breakpoint  cluster  region”  (bcr),  after  which  the  gene
localized to this region was denominated 15-16. Characterization of an mRNA molecule
specific to CML later revealed the fusion of two genes: the 5´part of BCR and 3´ part of
ABL. A chimeric protein product was therefore suspected to be involved in the malignant
process 17-18. The fusion transcript was indeed translated to a novel 210 kD
12
phosphoprotein (P210) whose ABL part had an altered tyrosine kinase activity when
compared to normal c-ABL protein product 19-20.
The transforming potency of BCR-ABL fusion gene was later established by using a
murine model. Bone marrow cells infected with retrovirus that encoded the BCR-ABL
fusion gene were transplanted into lethally irradiated mice. The transplanted cells induced
hematologic malignancies in 40-50% of the recipients, of which the most prominent one
was a myeloproliferative disorder that resembled CML in humans 21-23. The stimulus that
lead to the uncontrolled proliferation of the bone marrow cells already thought by
Dameshek was thereby a fusion gene encoding a chimeric protein with increased tyrosine
kinase activity.
2. Clinical characteristics of CML
Today it is known that the purulent-like material or white blood observed by Bennett and
Virchow was actually composed of excess of white blood cells, leukocytes, which is
typical of leukemias. Chronic myeloid leukemia (CML) is a malignant blood disease that
originates  clonally  from an  aberrant  pluripotent  hematopoietic  (blood  forming)  stem cell
affecting myeloid, monocytic, erythroid, megakaryocytic, B-cell and occasionally T-cell
lineages, even though the involvement of the last one is somewhat controversial 24-27. The
peripheral blood count in CML is characterized by a marked overrepresentation of
neutrophils and their precursors, but also the number of eosinophils and basophils is
increased. The platelet count is normal or increased and mild anemia is relatively common
28.
The bone marrow is hypercellular due to the excess of granulocytic series. The blast
count is usually normal; <5% of the marrow cells. Megakaryocytes are smaller than
normal and have an aberrant nuclear morphology (minimegakaryocytes) 28. The
photographs of peripheral blood and bone marrow samples of a patient with chronic phase
CML are presented in Figure 2.
Figure 2 Figures of peripheral blood (left) and bone marrow (right) smears of a CML patient
in chronic phase, showing leukocytosis in the peripheral blood, and hypercellularity
in the bone marrow due mainly to neutrophils in different stages of maturation. In
CML bone marrow, typical megakaryocytes are smaller than normal and have
hypolobulated nuclei. Courtesy of Dr. Satu Mustjoki.
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2.1. Epidemiology
CML is  one  of  the  most  common of  the  chronic  myeloproliferative  disorders,  but  still  a
rare disease worldwide. It accounts for 15-20% of all leukemia cases. The annual
incidence of the disease is approximately 1 case per 75 000 - 100 000 of population. There
is a slight male predominance, with a male-to-female ratio 1.3 to 1. CML patients are most
often diagnosed between the fourth and sixth decades of life 28-30,  but the median age of
the newly diagnosed CML patients is decreasing due to earlier time point of diagnosis. As
prognosis of CML is improving with current therapies, prevalence of the disease is
steadily increasing. CML can also be diagnosed in children, but childhood CML is
extremely rare, as it affects approximately one case per one million children annually 31.
Factors predisposing to CML are not known. Exposure to ionizing radiation has been
implicated in some cases 28, but majority of cases arise sporadically without any know
causative factor.
2.2. Clinical course of CML
The disease course of CML can be divided in two or three phases: relatively indolent
chronic phase, which is followed by more aggressive transformed stages, accelerated
phase and blast crisis. The blast crisis may not always be preceded by the accelerated
phase. The great majority of the patients are diagnosed in chronic phase. Currently most
patients are asymptomatic at the time of diagnosis as they are diagnosed incidentally
during routine blood tests showing abnormal blood counts. Common findings at the time
of diagnosis are fatigue, weight loss, anemia, night sweats and enlarged spleen (i.e.
splenomegaly). If untreated, the chronic phase is inevitably followed by transformation to
advanced phases.
Accelerated phase of CML is characterized by increase in total white blood cell count and
spleen size and the disease is more refractory to the therapy (Table 1). The blast crisis is
the final phase of CML that resembles acute leukemia, which is characterized by
accumulation of immature blast cells in the bone marrow and blood. The blast crisis is
either  myeloid  or  lymphatic  of  origin.  The  performance  status  of  the  patients  in
transformed stages of the disease is worse due to severe anemia, thrombocytopenia and
spleen enlargement. The duration of the chronic phase is very variable lasting from a few
months to several years, which is due to differences in general heterogeneity in the disease
course or in the time point of diagnosing the disease  28, 32.
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Table 1. Definitions for accelerated and blast phases of CML according to WHO criteria
28.
Accelerated phase
(one or more features present)
Blast phase
(one or more features present)
? Blasts 10-19% of peripheral blood white
blood cells and/or of nucleated bone
marrow cells
? Peripheral blood basophils ?20%
? Persistent thrombocytopenia (<100x109/l)
that is unrelated to therapy or
? Persistent thrombocytosis (>1000x109/l)
that is unresponsive to therapy
? Increasing spleen size and white blood
cell count that are unresponsive to therapy
? Cytogenetic clonal evolution
? Blasts ?20% of peripheral blood
white blood cells or of nucleated
bone marrow cells
? Extramedullary blast proliferation
? Large foci or clusters of blasts in
the bone marrow biopsy
2.3. Risk scores
Because of variable disease course and duration of CP in CML patients a number of
scoring systems have been developed to evaluate the patient’s relative risk of disease
progression and death in addition to defining the phase of the disease. The Sokal system
classifies  the  patients  treated  with  conventional  chemotherapy  into  three  risk  groups
according to significantly different survival patterns: low, intermediate and high risk
groups.  The  Sokal  score  is  based  on  an  algorithm  that  consists  of  following  parameters
measured at the time of diagnosis: patient age, spleen size, platelet count and percentage
of circulating blasts. Sokal score may also be calculated using internet sites such as the
European LeukemiaNet CML pages 33 or ROC (Regionalt Onkologiskt Centrum/ Regional
Oncology Center) in Uppsala, Sweden 34. In Sokal score hazard ratios 0.8 and 1.2 are
assessed as boundary values to discriminate the low, intermediate and high risk groups
from each other 35.
The Hasford (Euro) score was developed to evaluate the survival of CML patients
treated with interferon-alpha –based regimens. Besides the parameters mentioned in Sokal
system, calculation of Hasford score also takes into account basophil and eosinophil
counts and also discriminates the patients into three groups in respect to survival times.
Hasford score may also be calculated at the European LeukemiaNet internet pages 33.
Hasford score values below 780 indicate low, 780-1480 intermediate and values over 1480
high risk, respectively 36.
The  risk  of  patients  directed  to  allogeneic  hematopoietic  stem  cell  transplantation
(alloHSCT) is evaluated according to the European Group for Blood and Marrow
Transplantation (EBMT) score which takes into consideration known pretransplant risk
factors: histocompatibility, disease stage at the time of transplantation, time from
diagnosis to transplantation and age and sex of donor and recipient. The risk scores vary
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from zero to 7 so that the higher the score the higher is the risk of transplant related
mortality 37.
For patients who have failed interferon alpha treatment and who are subsequently
treated with the current first-line treatment, imatinib, a new risk score has been developed.
This scoring system, called the Hammersmith score after the hospital where it was
generated, is based on features determined after three months of imatinib treatment. At
that time point low neutrophil count and 65% or more of Ph chromosome positive cells
defined patients into three risk groups: low, intermediate and high risk of disease
progression at two years of treatment 38.  However,  this  scoring  system  needs  to  be
validated on a larger number of patients.
2.4. Immunological background of CML
Most if not all cancers become metastatic and lethal by virtue of escape from immune
system mediated control of abnormal malignant cells. The detailed mechanisms of cancer
immune surveillance are unresolved, but include both humoral and cellular defenses 39.
Different tumors vary considerably in their sensitivity to immune-mediated therapy, such
as vaccines and cytokine therapies.
CML is known to be a highly immunogenic malignancy based on both clinical and
experimental evidence. Donor immune system cures CML after alloHSCT. Upon relapse
after transplantation, donor lymphocyte infusion is a particularly effective immunotherapy
in CML as compared to other leukemias as most patients re-enter remission 40.
A few patients also appear to be operatively “cured” following interferon alpha
therapy, although many of these patients still have detectable minimal residual disease
(MRD) 41.  It  is  intriguing  that  the  small  numbers  of  patients  who  have  remained  in
remission following imatinib discontinuation, were previously exposed to interferon 42. It
is thus likely that remissions induced by interferon alpha and imatinib are
immunologically distinct 43.
The recent immunotherapy approaches by BCR-ABL peptide vaccines also suggest an
establishment of immune surveillance by tumor specific cytotoxic T cells within the
patient 44. These patients have shown decreasing levels of MRD following the
immunotherapy vaccinations which goes beyond what might have been expected from
continuation of imatinib therapy alone. As yet these patients have not discontinued
imatinib treatment to determine whether remission will be maintained. Recent reports have
indicated that imatinib itself also has significant immunomodulatory effects, which might
be important in the long-term control of CML 45.
BCR-ABL transcripts have also been detected in healthy individuals using sensitive
PCR –based techniques 46-47, which further underlines the importance of loss of immune
control in individuals developing clinical disease.
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3. The cytogenetics of CML
3.1. Standard Ph translocation
Chronic myeloid leukemia is cytogenetically characterized by presence of the Philadelphia
(Ph) chromosome. Approximately 90-95% of CML patients are Ph chromosome positive
in cytogenetic analysis of the bone marrow samples 18. The Ph chromosome is formed in a
reciprocal translocation between the long arms of chromosomes 9 and 22. After the
translocation event the distal part of the Ph chromosome therefore contains material from
chromosome 9 and the distal part of the derivative chromosome 9 contains material from
chromosome 22, respectively. An example of a standard 9;22 translocation positive cell is
presented in Figure 3.
Figure 3 A G-banded karyogram of a CML patient with standard translocation
t(9;22)(q34;q11.2). The Ph chromosome is indicated with an arrow.
3.2. Variant Ph translocations
In 5-10% of the CML cases the Philadelphia chromosome is formed as a result of a variant
translocation, in which other chromosomes in addition to 9 and 22 are involved. Variant
translocations can be divided into two groups in respective to the number of chromosomes
participating in the aberration. In simple variant translocations most often chromosome 9
(only rarely 22) has been replaced by some other chromosome so that cytogenetically the
abnormality seems to involve only two chromosomes, one of which is chromosome 22
(rarely chromosome 9) like t(V;22) or t(V;9) where V represents “the variant
chromosome”. Complex variant translocations are aberrations that concern one or several
other chromosomes besides 9 and 22, like t(V;9;22) 48.  Figure  4  depicts  a  case  with
complex variant translocation involving altogether four chromosomes. Still, whatever the
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type  of  Ph  translocation  is  detected,  the  key  point  is  the  same:  the  involvement  of
chromosomal areas 9q34 and 22q11.2 that leads to the BCR-ABL gene fusion in the
breakpoint region. In fact, chromosomal region 9q34 is a participant also in simple variant
translocations, even though this may not be cytogenetically discernible. All variant
translocations are therefore truly complex ones 48.
Figure 4 A G-banded karyogram of a complex variant translocation involving four
chromosomes. The karyotype is assigned as 46,XX,t(2;9;22;12)(q13;q34;q11.2;q13).
The prognostic significance of the Ph translocation type has been a matter of debate for
many years. Results supporting both equal prognosis and worse prognosis of CML
patients with variant translocation compared to standard translocation have been
published. Current data is however largely based on relatively small series of patients or
case reports. In addition, the treatment modalities have been changed substantially over
the years. The most common interpretation seems to be that the translocation type itself
does not have a prognostic influence 49. However, the higher frequency of submicroscopic
deletions of derivative chromosome 9 (reviewed in chapter 3.4.) may have accounted for
the worse outcome in CML patients with variant translocations observed in some studies
50-51.  The advent of imatinib as the first-line treatment has changed the rates of response
and overall survival in CML when compared to other treatments 52-53.  Therefore data on
the impact of Ph translocation type on the prognosis during imatinib treatment is of
interest in current management of CML. One study focused on variant Ph translocation
patients and reported similar prognosis to standard Ph translocation patients when treated
with imatinib therapy 54.
3.3. Ph negative, BCR-ABL fusion positive CML
Small  proportion  of  patients  has  a  clinical  picture  consistent  with  CML,  but  no  Ph
chromosome can be cytogenetically observed. In these cases the chromosomal aberrations
are  submicroscopic  and  in  conventional  cytogenetic  studies  the  cases  seem  to  be  Ph
chromosome negative. These may also be called as cryptic translocations or masked Ph
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chromosomes 48. However, even though cytogenetically no abnormality may be observed,
at the molecular level the pathogenic BCR-ABL fusion gene characteristic for CML is
detectable. This condition is called Ph negative, BCR-ABL positive  CML.  The  Ph
negative, BCR-ABL positive cases do not otherwise differ from standard Ph positive
patients except that the chromosomal mechanism of the fusion gene formation is instead
of translocation most often insertion of 3´ABL or 5´BCR sequences to chromosome 22 or
9, respectively 55-58. The latter one is exemplified in figure 5.
Figure 5 A mitotic cell of a Ph chromosome negative, BCR-ABL gene fusion positive CML
patient studied by fluorescence in situ hybridization (FISH). The yellowish fusion
signal in the proximal part of chromosome 9 long arm represents BCR-ABL gene
fusion. Single red and green signals indicate normal ABL and BCR genes,
respectively.
The “real” Ph negative cases that are also lacking BCR-ABL molecular rearrangement are
regarded as separate entities: as chronic neutrophilic leukemia or atypical CML. These
disorders are classified as either other chronic myeloproliferative or myelodysplastic/
myeloproliferative diseases according to WHO classification 59-60. Usually these diseases
are unresponsive to tyrosine kinase inhibitors and have a poor prognosis. Because of
unresponsiveness to these inhibitors the name (regardless of the prefix “atypical”) CML is
slightly misleading.
3.4. Deletions of the derivative chromosome 9
The discovery of deletions in the translocated chromosome 9, i.e. derivative chromosome
9, der(9), resulted from the development and further refinement of probes used in FISH
assays. More distinguished probe sets were designed for detection of both the Ph
chromosome and the der(9) in minimal residual disease analyses in order to reduce the
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number of false-positive findings that were relatively common when more conventional
probes were used in the assay 61-62. However, in some patient samples an aberrant signal
pattern was unexpectedly observed. The fusion signal indicating the BCR-ABL gene in the
Ph chromosome was visible, but der(9) chromosome was lacking a signal of its own. This
finding was indicative for a deletion in der(9), a phenomenon not reported earlier. The
presence of a deletion was further confirmed by PCR targeting microsatellite loci and
additional FISH probes mapping on the deleted region 63-64.
Ever since the initial findings, large deletions in der(9) chromosome translocation
region have been identified in 10-15% of CML patients in Western countries 63-65. For an
unknown reason the reported frequency of der(9) deletions is higher in Asian populations,
being over 20% 66-68. Patients with variant translocation have more often der(9) deletions
than patients with standard translocation, as the approximate frequency is 40% 50-51, 69.
Der(9) deletions have also been observed in Ph chromosome positive ALL, with a similar
frequency as in CML 70.
The der(9) deletions have variable breakpoints and the size of the deleted region ranges
from a few hundred kilobase pairs to several megabase pairs of DNA 63-64, 71. In most cases
the deletions span the translocation breakpoint and contain material from both
chromosomes 9 and 22. The other deletion types contain only chromosome 9 sequences
upstream the ABL gene, or only chromosome 22 derived sequences, respectively 72-73. The
different deletion types detected by FISH are indicated in Figure 6 (B-D).
Figure 6 Different deletion types in der(9) as assessed by “dual color dual fusion” pattern
FISH probe. A) Conventional signal pattern in a Ph chromosome positive metaphase
cell without a der(9) deletion. B) Der(9) deletion containing both the 5´ABL and
3´BCR sequences. C) Der(9) deletion of only the 5´ABL, and D) containing only the
3´BCR sequences.
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3.4.1. When are der(9) deletions formed?
The  der(9)  deletions  are  commonly  regarded  as  occurring  at  the  time  of  the  Ph
translocation, since distinct patient populations in different phases of CML have been
found to exhibit nearly identical frequencies of cases with deletions. Likewise, paired
samples taken at the time of diagnosis and at disease progression of the same patients have
been analyzed with consistent results 63, 69, 74. In few reports though, the deletion has been
described as a secondary event, since cells with and without the deletion have been
observed simultaneously 68, 75, but the majority of the current literature is in support of
simultaneous translocation and deletion events.
3.4.2. The clinical impact of der(9) deletions
In the first published studies patients with der(9) deletions were found to confer poorer
prognosis when compared to patients without deletions. Significant difference in overall
survival was observed between the deleted or non-deleted groups. The deletion was found
to be an independent prognostic factor and more powerful than Sokal or Hasford scoring
systems 63, 69, 76.  The size of deletion was observed to confer prognostic significance: the
larger deletions were associated with poor prognosis, whereas smaller ones have no
prognostic impact 72-73.
The poor prognosis of der(9) deletions was discovered in patient populations treated
mainly with interferon-alpha based regimens. Since the advent of imatinib the prognostic
significance of der(9) deletions has been re-evaluated in a few studies. In one study, the
rates  of  hematologic  and  cytogenetic  response  were  lower  in  patients  with  deletions,
although the difference was not significant when only newly diagnosed patients were
selected for analysis 77.  In  another  study,  no  difference  in  response  rates  was  observed,
even if the der(9) deletion patients were receiving more often higher imatinib dose than
cases without deletion 78. This finding has also been confirmed in studies with equal
imatinib dose 79-80. However, results of deletion positive chronic phase CML patients
treated with second generation tyrosine kinase inhibitors may indicate worse survival, but
the reason for this disparity is not clear 81. As the prognostic significance of der(9) deletion
is not so clear in CML treatment, it has been considered as a warning sign being one
candidate adverse prognostic factor 82.
3.5. Clonal evolution
The majority of CML patients develop secondary (i.e. additional) clonal aberrations in Ph
positive cells in advanced phases of the disease. Additional abnormalities can be detected
in approximately 75-80% of CML patients in blast crisis. The appearance of secondary
changes is a phenomenon called cytogenetic clonal evolution. Clonal evolution is thought
to be reflecting genetic instability of the leukemic cells and may be a sign of disease
progression 49, 57, 83.
Secondary chromosomal aberrations are clearly non-random, the most common ones
being the isochromosome 17q, trisomy 8, additional Ph chromosome and slightly less
frequently trisomy 19 [i.e. i(17)(q10), +8, +der(22)t(9;22)(q34;q11.2), +19]. The first three
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changes constitute over 90% of the CML cases in whom secondary chromosomal changes
are being detected. These and other aberrations occurring at frequencies exceeding 5% are
called “major route” abnormalities. Other, less frequently seen abnormalities are called
“minor route” changes, being for example trisomy 21 and monosomies of chromosomes 7
and 17 49, 84.
The prognostic significance of specific secondary chromosome abnormalities is
variable. Many studies have reported that blast crisis without secondary abnormalities
might have a better prognosis. Other investigations have not found such a connection. In
all, the prognostic impact of secondary abnormalities is heterogeneous and most likely
linked to various other parameters, including time of appearance, types of aberrations and
also treatment modalities 49.
3.6. Clonal chromosomal changes in Ph negative cells
Other clonal chromosome aberrations can also be detected in Ph chromosome negative
cells. This relatively new finding was observed during cytogenetic monitoring of CML
patients treated with imatinib. The patients have achieved cytogenetic response to the
treatment, but unexpectedly other clonal chromosome aberrations were seen in Ph
negative cells. The incidence of these other clonal aberrations is relatively low, being 2-
15% of the imatinib treated patients depending on whether the patients have been studied
from selected or unselected cohorts. A small fraction of patients with Ph negative
abnormalities develop bone marrow myelodysplasia, or myelodysplastic syndrome. Most
frequently observed chromosome abnormalities are numerical aberrations, mainly -Y, +8
and -7. Structural changes are observed less frequently, out of which deletions of long
arms of chromosomes 7 or 20 (7q-, 20q-) are more commonly seen 85-88.
The mechanism of the formation of aberrant Ph negative clones is not clear. In small
proportion of patients the presence of Ph negative clone has been shown in samples
preceding imatinib treatment. This would indicate the expansion of pre-existing clone after
eradication of Ph positive cells by imatinib. However, this has not been detected in all
patients, so direct effect of imatinib can not be totally excluded, even though it is unlikely
87, 89-90. Ph negative clonal hematopoiesis has also been detected during dasatinib
treatment, so the phenomenon is not restricted only to imatinib therapy, but concerns other
tyrosine kinase inhibitors as well 91-92.
Just like the origin, the clinical significance of clonal aberrations in Ph negative cells is
not unequivocal. The appearance of clonal abnormalities in Ph negative metaphases may
be transient, occurring only once, but the cells may also persist or even increase in time.
The prognostic impact of Ph negative clonal aberrations needs further clarification, but
chromosome  7  changes,  in  particular  monosomy  7,  appears  to  have  the  greatest  risk  of
developing myelodysplastic syndrome or acute myeloid leukemia. Aneuploidies of
chromosomes  Y  and  8  (-Y  and  +8)  seem  more  indolent 93. In practice, periodical
monitoring of CML patients with conventional cytogenetics has clear importance because
of the variable clinical significance of these abnormalities.
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3.7. Ph chromosome in other hematological malignancies
The Philadelphia chromosome is not however, exclusively detected in CML. It has also
been reported in B-cell acute lymphoblastic leukemia (ALL) 94. About 25% of adults and
5% of children diagnosed with ALL show Ph in chromosome analysis 95 In addition, rare
cases (<1-4%) of acute myeloid leukemia present Ph chromosome at diagnosis 96-97. Some
of the cases may actually represent CML diagnosed not until in the lymphoid or myeloid
blast crisis. The prognosis of Ph chromosome positive acute leukemia is poor when treated
with conventional cytotoxic therapy. Some patients may be cured by allogeneic
hematopoietic stem cell transplantation. The advent of broad-spectrum tyrosine kinase
inhibitors may dramatically change the prognosis of Ph+ ALL.
4. Molecular genetics and pathology of CML
At the molecular level, the primary genes affected in CML are ABL and BCR.  The  Ph
translocation gives rise to a chimeric fusion gene, BCR-ABL, with constitutive kinase
activity leading to enhanced cell proliferation, resistance to apoptotic stimuli and altered
cell adhesion. The cellular functions of normal and fused genes in CML are reviewed
below.
4.1. Oncogenic tyrosine kinases in hematological malignancies
Protein tyrosine kinases are enzymes that phosphorylate tyrosine residues of various
substrate proteins and thereby regulate their activity. The target of the phosphorylation
may be the kinase itself (autophosphorylation) or other proteins downstream of various
signaling pathways. Tyrosine kinases regulate the intracellular signal-transduction
pathways and therefore have an important role in cell proliferation and differentiation 98-99.
Constitutive activation of various tyrosine kinases has been described in many types of
malignancies. Oncogenic tyrosine kinases can be products of chimeric fusion genes
generated through chromosomal rearrangements such as translocations or deletions. They
can also be formed through gene mutations leading to constitutive activation, or gene
amplifications leading to overexpression. Tyrosine kinases can be divided into
transmembranic, ligand-binding receptors such as the stem cell factor receptor C-KIT, or
cytoplasmic, intracellular non-receptor kinases like ABL 98, 100-101.
4.2. Abelson murine leukemia viral oncogene homolog 1 (ABL) gene
The tyrosine kinase ABL is encoded by the Abelson murine leukemia viral oncogene
homolog 1 (ABL, ABL1) gene located in the chromosome region 9q34.1. The ubiquitously
expressed ABL protein localizes to both the cytoplasm and nucleus of the cells and is able
to shuttle between these two compartments 102-105. The ABL gene  contains  a  total  of  11
exons, of which the first one (1a or 1b) is alternatively spliced. The transcription of ABL
generates  two  distinct  messenger  RNAs  (mRNA)  5  kb  and  6.5  kb  of  size  which  are
translated to two 145 kD protein isoforms (Ia and Ib) differing in their first 19
aminoterminal residues (reviewed by Van Etten) 106-107.  The  isoform  Ib  contains  a  C14
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myristoyl fatty acid linked to its amino terminus and is expressed at higher levels than the
unmyristoylated Ia form 108-110. The functional domains of ABL are presented in Figure 7.
ABL has been implicated in several cellular processes, such as regulation of cell
proliferation, differentiation, adhesion, and cell death. ABL both promotes and inhibits
cell growth. In quiescent cells ABL is kept inactive by binding to RB protein, which when
phosphorylated dissociates and activates ABL during the S phase of the cell cycle. ABL in
turn, activates other genes in a growth-promoting way. However, some studies have
shown that overexpression of ABL induces cell-cycle arrest in G1 phase 106.
Nuclear ABL is involved in regulation of the cell cycle and response to genotoxicity,
whereas  cytoplasmic  ABL  has  a  role  in  signaling  and  cytoskeletal  molding 111. Nuclear
ABL has also been implicated in DNA damage-induced apoptosis. After DNA damage
ABL gets activated as a result of ATM function and RB inactivation. ABL-induced
apoptosis is then mediated through the p53 and the p53-homologue p73 protein leading to
growth arrest or apoptosis 112-114. ABL gets activated as a response to cellular stress, such
as ionizing radiation or oxidative stress. The stress-activated mitogen-activated protein
kinase (MAPK) family members JUN N-terminal kinase (JNK/SAPK) and p38 also have
a role in mediating ABL-induced cell death 100, 106, 114. Cytoplasmic ABL associates with
actin fibers, which form the basic structure of cytoskeleton, and is therefore involved in
PDGF-induced response to motility and cell adhesion 100, 115.
The tyrosine kinase activity of normal ABL is tightly controlled. The residues at the
extreme amino terminus of the ABL protein form a “cap” structure that is present in both
splice variants. The cap structure inhibits the kinase activity of the protein by
intramolecular binding to the SH3 and catalytic domains, leading to autoinhibition 116,
reviewed in 117. The myristoyl modification in Ib isoform also has a role in regulating the
kinase activity by binding to the catalytic domain 109, 118.  The  regulation  of  the
unmyristoylated ABL Ia isoform remains to be determined 119.
Figure 7 Schematic structure of the ABL protein. ABL contains SRC homology domains SH1,
SH2 and SH3, of which SH1 operates as the tyrosine kinase domain. SH2 and SH3
serve as binding sites for different proteins, SH2 for phosphotyrosine residues and
SH3 for proline-rich sequences. PxxP indicates proline-rich regions, which are able
to bind SH3 domains. Nuclear localizing signals (NLS) and one nuclear-export signal
(NES) balance the amount of protein accumulating in the cell nucleus. The DNA-
binding domain has a role in chromatin binding of the nuclear ABL. Binding of ABL
to actin filaments in the cytoplasm is mediated by G- and F-actin binding domains
(GBD, FBD). The saw-edged sign indicates the breakpoint region in ABL. The figure
is modified from references 119 and 120 and the functions of the indicated domains are
based on references 104-105 and 121-123.
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4.3. Breakpoint cluster region (BCR) gene
The normal functions of the Breakpoint cluster region (BCR) protein are known less than
the ones of ABL. The BCR gene localized to chromosome 22q11.2 consists of 23 exons, of
which the first two have alternative exons in intron 1 124-126. Two different mRNAs 4.5 kb
and 7kb of size, coding for 130 kD and 160 kD proteins, respectively, have been found 18,
124, 127. The ubiquitously expressed BCR was first regarded as a cytoplasmic protein, but
later studies have shown its capability to associate with condensed DNA 128-130.
The BCR protein has a serine/threonine kinase activity encoded by the first exon of the
BCR gene 131. It also interacts with G proteins, like GTP-binding protein p21Rac, involved
in intracellular signaling, cytoskeleton organization, cell growth and normal development
111, 132. BCR has also been implicated in regulating the WNT signaling pathway 133 and has
a role in cellular trafficking of growth factor receptors 134. Additionally, BCR interacts
with the xeroderma pigmentosum B (XPB) protein, possibly linking BCR to DNA repair
111, 135. The functional domains of BCR are indicated in figure 8.
Figure 8 Schematic structure of the BCR protein. The amino terminus contains the coiled-coil
oligomerization domain that mediates the tetramerization and activation of the
protein. Tyrosine 177 residue has a function in binding to growth factor receptor-
bound protein 2 GRB2, an adapter molecule involved in the RAS pathway activation.
The guanidine exchange factor (GEF) domain activates G-proteins, whereas the
carboxyterminal guanosine triphosphate-activating protein (GAP) domain inactivates
G proteins. The saw-edged markers indicate the breakpoint regions in BCR. The
figure is modified from ref. 111 and the functions of the indicated domains are based
on references: 132, and 135-138.
4.4. The BCR-ABL fusion gene
The molecular basis of CML is the formation of the BCR-ABL fusion gene as a result of
Ph translocation. The 5´part of the gene consists of BCR derived exons and the 3´end of
ABL originating sequences. The breakpoints in ABL lie at the 5´part of the gene, upstream
of exon 2 (termed a2). In the vast majority of CML patients (95%) and approximately one
third of Ph+ ALL patients the BCR gene breaks in the 5.8 kb breakpoint cluster region
(bcr) spanning exons 12 to 16 (formerly referred as exons b1-b5), termed the major bcr
(M-bcr).  As  a  result  of  alternative  splicing,  either  b2a2  or  b3a2  (also  called  e13a2  and
e14a2, respectively) transcripts are formed (Figure 9). The 8.5 kb fusion mRNAs are then
translated into chimeric 210 kD proteins (p210) 19-20, 139. In contrast to the normal
counterparts, the BCR-ABL protein isoforms are present exclusively in the cytoplasm 128.
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Two other breakpoint cluster regions in the BCR gene have also been characterized:
the minor-bcr (m-bcr) and micro-bcr (?-bcr) regions. The m-bcr is mainly associated with
Ph+ ALL (approximately two thirds of the cases) and is detected only occasionally in
CML. The m-bcr breakpoint is situated proximally to M-bcr, between alternative exons
e2´and e2 (Figure 9). Due to alternative splicing the 7.0 kb fusion transcript has an e1a2
junction and is translated into a 190 kD protein (p190) 140-141. However, p190 can also be
detected at low levels in p210 positive CML 120, 142. In a small subset of CML patients the
BCR breakage occurs distally downstream of exon 19 in the ?-bcr region generating a 9 kb
mRNA that is translated into a 230 kD protein (p230) (Figure 9). This c3a2 (e19a2) type
of fusion is associated with a neutrophilic CML that is regarded as a more indolent
disease, but it has also been detected in classical CML 143-145.
In rare occasions (<5% of CML cases) other kind of BCR-ABL junctions, such as b2a3,
b3a3, e1a3, e6a2 and e8a2 have been described. The breakpoints in ABL and BCR are
variable and they can even be located within exons 146. Some aberrant fusion transcripts
may also contain small insertions or intervening sequences between BCR and ABL 147-149.
The use of multiplex reverse transcriptase PCR techniques in the diagnosis of CML cases
also detects these unusual fusion transcripts 150-151.
Figure 9 BCR-ABL fusions on a genomic level. The genomic structures of ABL and BCR genes
are represented in the upper part of the figure. The chimeric mRNAs derived from the
fusion genes and proteins with their corresponding molecular weights are marked at
the lower part of the picture. The figure is modified from ref. 120.
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4.5. Cellular signaling pathways affected by BCR-ABL
The structure of the BCR-ABL fusion protein (presented in Figure 10) and the signaling
pathways affected by its expression have been widely studied 120, 151. Three main
mechanisms have been implicated in the transformation process of the BCR-ABL fusion
protein: altered adhesion to stroma cells and the extracellular matrix, constitutively active
mitogenic signaling and reduced apoptosis.
During normal hematopoiesis, the hematopoietic progenitor cells adhere to bone
marrow stromal cells and the extracellular matrix which is considered essential for the
regulation of hematopoiesis through cytokine mediated signaling. As BCR-ABL protein
expression leads to altered adhesion, the CML cells are lacking the regulatory signals that
are provided to normal hematopoietic cells 152. One of the most prominent
phosphorylation targets of BCR-ABL, the CRKL protein has been implicated in cellular
motility and in integrin-mediated adhesion by associating with focal adhesion proteins like
paxillin, FAK, p130CAS and HEF1 151, 153-156.
BCR-ABL activates several signaling pathways known to have mitogenic potential.
Autophosphorylation of tyrosine 177 of the fusion protein promotes binding of the adapter
molecule GRB2 which in turn, through association with the SOS protein stabilizes RAS in
its active form 157-158. Activation of RAS induces a signaling cascade via the mitogen-
activated protein kinase (MAPK) pathway leading to antiapoptotic BCL2 expression 159-
160. BCR-ABL also activates other signaling pathways such as the signal transducer and
activator of transcription 5 (STAT5) and phosphatidylinositol 3-kinase (PI3K)/AKT
pathways, leading to transcriptional activation of BCL-XL and antiapoptotic signaling and
CML cell proliferation 161-163. In addition, CML cells inhibit apoptosis by phosphorylation
of the proapoptotic BAD protein or by repressing the expression of interferon consensus
sequence binding protein (ICSBP) that regulates the expression of apoptosis related genes
164-166. Even though much is known about the protein-protein interactions of BCR-ABL
the cellular mechanisms of action of the fusion protein, such as its critical effector
molecules, are still unknown. Therefore, further studies are needed to elucidate the
molecular and cellular biology of CML 119, 167-168.
Figure 10 Schematic structure of the BCR-ABL fusion protein isoforms. The coiled coil
oligomerization domain (OD) and the tyrosine residue 177 (Y177) in the BCR part of
the fusion protein are essential for inducing CML-like myeloproliferative disease in
murine models 136, 169. The figure is modified from figures 7 and 8 and the references
therein.
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5. The role of genetic analyses in diagnostics and follow-up of CML
5.1. Analyses performed at the diagnostic phase
The diagnosis of CML is confirmed by the presence of Ph chromosome and/or BCR-ABL
fusion transcripts. Additionally, other complementing tests may be performed, e.g.
determination of the BCR-ABL transcript type or the deletion status of der(9).
The presence of the Ph chromosome is usually shown by conventional cytogenetics in
bone marrow sample, using most often G-banding method. Conventional cytogenetics is
“a genome-wide screen” at its own sensitivity level for detecting other abnormalities. The
type of Ph translocation is also defined in G-banding study. Usually 20 mitotic cells are
analyzed in cytogenetic analysis. Conventional cytogenetics is often accompanied by a
fluorescence in situ hybridization (FISH) assay using a locus-specific BCR and ABL
probes labeled with different fluorescent dyes. FISH detects the presence and localization
of BCR-ABL fusion gene also in cases with Ph negative BCR-ABL positive disease and the
possible presence and type of der(9) deletion 170-171.  The latter is  important not only as a
potential prognostic marker but is also essential piece of information when considering
interphase FISH as a follow-up technique due to low mitotic index.
Molecular genetic analyses at the diagnostic phase focus on demonstration of the BCR-
ABL fusion transcript. This is usually performed with RQ-PCR or with qualitative
multiplex-PCR systems that also detect more rare fusion types. Molecular genetic analyses
on diagnostic sample based on RQ-PCR offer the patient-specific baseline for molecular
monitoring and defining the level of treatment response.
5.2. Follow-up studies and minimal residual disease analyses
The response to the given therapy - whether it is a tyrosine kinase inhibitor such as
imatinib or an allogeneic hematopoietic stem cell transplantation (alloHSCT) - is
evaluated with cytogenetic and molecular genetic tests 172-175. Especially during tyrosine
kinase inhibitor therapy the level of minimal residual disease (MRD) is regularly assessed
during follow-up. MRD describes a situation in which the conventional laboratory
analyses, such as morphological studies and chromosome analyses performed with
standard G-banding, are unable to detect leukemic cells, but when more sensitive
techniques are used, residual CML cells are observed. Metaphase FISH and RQ-PCR
assays are the techniques used for MRD detection in CML.
5.2.1. Cytogenetic follow-up analyses
The current first-line treatment, imatinib (reviewed in detail in chapter 6.1.) induces
complete  cytogenetic  responses  (CCyR,  i.e.  no  Ph  positive  cells  detected  in  the  cell
population analyzed) in over 70% of CML patients during the first 18 months of treatment
and nearly 90% during five-year follow-up 52, 176. These analyses were performed with
conventional cytogenetics, which is a rather crude tool for investigating residual disease as
the analysis of 20 metaphase cells excludes only 14% level of mosaicism (i.e. presence of
cells with different karyotype in a same sample) 177. The levels of cytogenetic response are
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presented in Table 2. Conventional cytogenetics is irreplaceable in detecting clonal
evolution in Ph positive cells or other clonal abnormalities in Ph negative hematopoiesis.
Table 2. The terms and levels of cytogenetic response. The data is adopted from Baccarani
et al.2006 82.
Level of cytogenetic
response
Frequency of Ph positive
metaphases (%)
Complete (CCyR) 0 %
Partial <35 %
? Major cytogeneticresponse
Minor 36-65 %
Minimal 66-95 %
None >95 %
Cytogenetic response and MRD status may be defined more extensively than conventional
karyotyping with FISH methods targeting the BCR and ABL genes  at  the  chromosomal
level. Metaphase FISH monitors the presence of mitotic i.e. dividing leukemic cells 178.
Prolonged treatment with colcemid and sufficiently high number of nucleated cells in cell
culture provides the acquisition of high number of mitotic cells for MRD analyses 179. The
term “hypermetaphase FISH” has also been used in this technique 180. Different cytokine
cocktails in cell culture in addition to long-term mitotic arrest with colcemid can also be
applied 181-182.
Conventional karyotyping or metaphase FISH require dividing cells and therefore a
bone marrow aspirate as a sample for analyses. Peripheral blood sampling would provide
less invasive method of assessing disease burden, but the lack of mitotic cells does not
allow extensive analyses at chromosomal level. Interphase nuclei in blood cells may be
analyzed with locus-specific FISH probes, but the relatively high rate of false positive
findings (1-5% depending on the probe and laboratory specific factors) may complicate
the interpretation of low-level Ph positivity. The presence of der(9) deletion complicates
the analysis of interphase cells and makes the interpretation of rare positive-looking cells
even more difficult. The addition of third probe may improve the quantification of
minimal residual disease in these cases 183.
5.2.2. Molecular genetic follow-up studies
Techniques based on the PCR method are the most sensitive way of assessing residual
disease in CML patients. The most commonly used method is nowadays RQ-PCR which
enables the determination of actual BCR-ABL transcript copy numbers in proportion to the
copy numbers of a reference gene. Some years ago the “Europe Against Cancer” (EAC)
Concerted Action published a standardization and quality control study for detecting nine
fusion gene transcripts for residual disease in different types of leukemia with RQ-PCR.
For  CML  and  Ph+  ALL  the  most  common BCR-ABL fusion transcript types were
included; namely M-bcr (b2a2 and b3a2) for p210 and m-bcr (e1a2) for p190 coding
sequences, respectively. This published protocol and the accompanying publication about
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the recommended reference genes are followed by many molecular genetic laboratories
184-185.
The importance of molecular monitoring of CML patients with RQ-PCR became
evident after the advent of imatinib treatment and the phase III trial (reviewed in chapter
6.1.2.). In 57% of the patients who had achieved CCyR during the 12 months of imatinib
treatment, the levels of residual BCR-ABL transcripts had fallen by 3 logarithmic units or
more, indicating major molecular response (MMR) to the treatment. In this patient group
the probability of remaining progression free was 100% at 24 months 172. This progression
free time was actually extended to 60 months of treatment when the 5-year follow-up data
of the phase III trial was published 52. The three-log reduction by 18 months has therefore
become a prognostically significant value indicating optimal response to imatinib
treatment.
5.2.3. International standardization of RQ-PCR assays in minimal residual disease
analytics
The RQ-PCR methodologies used for detecting residual BCR-ABL transcripts are variable,
including the type of PCR-machinery, chemistry, the origin of samples and the choice of
the reference gene. Additionally, the results can be reported either as a BCR-
ABL/reference gene copy number ratio, a percentage of the ratio, difference between Ct
values (??Ct), or a logarithmic reduction of transcripts compared to a baseline value. All
this variability complicates the comparison of RQ-PCR results obtained from different
laboratories 172, 186-189.
Recently, detailed recommendations on harmonizing RQ-PCR assays have been
published aiming for world-wide standardization of this technique. The recommendations
included a variety of practical issues concerning laboratory technical part of the assays,
but also sample types and the way on reporting the results were discussed 190-191.
Three equally suitable reference genes were proposed: ABL, BCR or GUS.  Of  these
ABL is  the  most  widely  used  despite  of  concurrent  amplification  of BCR-ABL with ABL
primers in the assays 191. A minimum of 5 to 10 ml of peripheral blood was recommended
as the sample type. Only one tissue type sample should be used consistently for
monitoring MRD, not to interchange of blood and bone marrow because of consistent
differences in BCR-ABL expression levels in different tissue types observed in some
patients 190. RNA extraction should be performed on total leucocytes, not fractionated
cells. Reverse transcription should be performed using random hexamers. Primers and
probes for the RQ-PCR assay should be RNA specific and take into account the
polymorphic site in BCR exon 13 192-194. Quality control samples of negative, high and low
expression levels of BCR-ABL should be included in the assays. Calibration standards
such as DNA plasmids are used for constructing standard curves and they should be
included in each assay to compensate for the variation due to probe degradation,
differences in reagent batches and also for the run to run variation observed even when the
same reagents are used 190.
Besides the recommendations for technical performance of the RQ-PCR assays, an
International  Scale  (IS)  was  proposed  for  expressing  the  MRD  results  in  a  standardized
way. The IS is anchored to two values defined in the phase III study: the standardized
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baseline represents 100% and the 3-log reduction corresponding to MMR equals to 0.10%
of BCR-ABL transcript level on the IS 191. Since the 30 diagnostic samples used for
determining the baseline in the phase III study 172 are no longer available and no
commercial reference samples are this far available, the standardization may be performed
by studying reference samples of known MRD level obtained from a reference laboratory
already applying the IS. This allows other laboratories to determine their own MRD value
of these reference samples. The difference between the values of the reference laboratory
and the laboratory studying the reference samples may be adjusted with a laboratory-
specific conversion factor so that after multiplying the MRD results with the conversion
factor the values would be comparable to the reference laboratory 191.
6. Treatment of CML
Treatment modalities of CML have changed considerably over the years. The treatment of
CML with cytotoxic chemotherapies such as busulfan and hydroxyurea lead to
hematological responses and reduction of disease-related symptoms, but did not provide
any survival advantage, so the disease inevitably progressed to advanced phases.
Interferon-alpha treatment produced not only hematological remissions but also
cytogenetic responses in approximately 20-60% of patients which was associated to
prolonged survival, but the use of interferon-alpha was also hampered by toxic side effects
for  a  proportion  of  patients 195-197. Molecularly targeted therapy with tyrosine kinase
inhibitors, most often imatinib, and allogeneic hematopoietic stem cell transplantation are
the therapeutic options reviewed below.
6.1. Imatinib: the current gold standard of CML treatment
Imatinib (Glivec®, Gleevec™, formerly STI571 or CGP57148B, also called imatinib
mesylate) is a selective small molecule tyrosine kinase inhibitor used in targeted treatment
of CML and Ph chromosome positive ALL 198. Imatinib is a 2-phenylaminopyrimidine
compound that  in  preclinical  studies  showed a  92-98% decrease  in  the  number  of  BCR-
ABL positive colony formation but had no inhibition on normal colonies. This observation
suggested the potential utility of the compound in the treatment of BCR-ABL-positive
leukemias 199.
In addition to BCR-ABL and ABL inhibition, imatinib also has affinity for the ABL
related ARG protein 200 and for the receptor protein-tyrosine kinases PDGFR?, PDGFRß
and C-KIT 199, 201-202. This makes imatinib an active drug for treating also other diseases
affected by aberrant kinase activity, such as gastrointestinal stromal tumors (C-KIT gene
mutations) 203, hypereosinophilic syndrome or chronic eosinophilic leukemia (FIP1L1-
PDGFR? gene fusion) 204. Chronic myeloproliferative disorders associated with e.g.
t(5;12)(q33;p13) or several other chromosome 5q33 aberrations, may result in the
rearrangements of PDGFRß gene that are also sensitive to imatinib 205. In addition,
patients with systemic mastocytosis positive with FIP1L1-PDGFR? fusion and with a rare
soft tissue sarcoma dermatofibrosarcoma protuberans (characterized by COL1A1-PDGFß
gene fusion that leads to autocrine stimulation of PDGFRß) may benefit from imatinib
treatment 206-208.
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6.1.1. The mechanism of imatinib kinase inhibition
The high specificity of imatinib in inhibiting the tyrosine kinases mentioned above is
achieved by its ability to bind the kinase molecule in its closed (inactive) conformation. In
the closed conformation the centrally located activation loop of the kinase is not
phosphorylated and therefore inactive. When phosphorylated, the activation loop extends
to the open (active) conformation which enables binding of substrate molecules to the
kinase and subsequently their phosphorylation. The active conformation is very similar in
all known kinases 209. In contrast, the inactive conformation has great diversity among
protein kinases, explaining the specificity of imatinib. Imatinib occupies the ATP binding
site of the BCR-ABL kinase domain and acts as a competitive inhibitor of BCR-ABL with
respect to ATP. The side chain of threonine residue at position 315 (T315) forms a
hydrogen bond with the imatinib molecule. This residue is replaced by methionine in
many kinases which is not able to form such a bond, which makes T315 a key element for
imatinib to inhibit BCR-ABL 209-210. When imatinib occupies the ATP binding pocket it
stabilizes the inactive form of BCR-ABL, thus preventing autophosphorylation of the
kinase itself and subsequently phosphorylation of its substrates. This consequently results
in inhibition of the signaling cascades downstream of BCR-ABL, inhibition of cell
proliferation, and eventually apoptosis (Figure 11) 199, 211-212.
Figure 11 The mechanism of imatinib mediated signal transduction inhibition. Imatinib
occupies the ATP binding pocket of BCR-ABL fusion protein and stabilizes the
inactive non-ATP-binding conformation of the kinase thereby contributing its
inhibitory actions towards BCR-ABL. The figure is adapted from the article of Savage
and Antman 2002 213. Copyright © 2002 Massachusetts Medical Society. All rights
reserved.
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6.1.2. The IRIS (International Randomized Study of Interferon and STI571) trial
The efficacy of imatinib in newly diagnosed CML patients was determined in a pivotal
phase  III  study,  also  called  the  IRIS  (International  Randomized  Study  of  Interferon  and
STI571) trial 176. A total of 1106 newly diagnosed chronic-phase CML patients were
randomized to receive either 400 mg of imatinib or interferon-alpha and cytarabine. The
data demonstrated superiority of imatinib over interferon and cytarabine in the treatment
of  newly  diagnosed  disease.  At  12  months  of  treatment  the  rates  of  major  and  complete
cytogenetic response (CCyR) were 85% and 74% in patients treated with imatinib,
compared to 22% and 9% in patients receiving combination therapy 176.
The IRIS trial also included a study evaluating the frequency of major molecular
responses (MMR) in patients who had achieved a CCyR to the treatment. In this study, a
reduction of 3 logarithmic units of BCR-ABL transcript levels from the diagnostic baseline
was detected in 57% of imatinib and 24% of interferon plus cytarabine treated patients at
12 months of treatment. The estimated rates of all study patients in achieving MMR was
39% in the imatinib group and 2% in combination therapy group, respectively. The CCyR
combined with 3-log reduction at 12 months indicated 100% of progression free survival
at 24 months compared to 95% of such patients with a reduction less than 3 log units and
85% for patients who had not achieved CCyR at 12 months 172.
Five-year follow-up results of the IRIS trial were published in 2006 52 and further
updated in 2007 214. At five years of follow-up there were only 16 (3%) patients left in the
interferon and cytarabine treatment group, so the report mainly focused on the patients
treated with imatinib as the initial therapy. By five years of treatment, the estimated rate of
event-free survival was 83% and for progression-free survival 93%, the number remaining
unchanged at six-year update. For long-term outcomes achievement of both CCyR and
MMR at 12 months indicated 100% progression free survival at 60 months of imatinib
treatment 52.
In a subset of the IRIS patients the long-term molecular follow-up results and the rates
of undetectable BCR-ABL levels were reported. During the first 18 months the BCR-ABL
levels reduced rapidly to MMR in the majority of patients and after that the BCR-ABL
transcripts continued to decline,  if  only at  slower rate.  The 12-month time point was the
best predictor for achieving undetectable BCR-ABL levels. The probability of achieving
undetectable BCR-ABL at 6 years for patients having a MMR at 12 months was 72%
compared to a probability of 5% in patients without a MMR at one year time point. Loss
of MMR was observed only in patients with constantly detectable BCR-ABL levels 215.
Imatinib has induced remarkable responses in early chronic phase CML patients.
However, the response rates have been lower and less durable in advanced phases of the
disease. Higher starting dose of imatinib (600mg) has proven superior to standard dose
both in accelerated and blast phases of CML and induced even CCyR in some patients, but
responses have been transient, lasting for some months in blastic phase CML 216-217.
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6.2. Allogeneic hematopoietic stem cell transplantation (alloHSCT)
The introduction of imatinib has changed the indications of hematopoietic stem cell
transplantation in the treatment of CML. The graft  is  composed of stem cells originating
from peripheral blood, bone marrow or cord blood. Stem cell grafts may be collected from
the patients themselves (autologous transplant) or from healthy family or unrelated donors
for alloHSCT. The transplanted patients are first treated with high-dose chemotherapy or
chemo-  and  radiotherapy  which  is  followed  by  transfusion  of  hematopoietic  stem  cells
from a healthy donor. The transfused stem cells engraft and reconstitute the patient’s
hematopoietic system. Before tyrosine kinase inhibitors were available, newly diagnosed
chronic  phase  CML  patients  under  60  years  of  age  with  a  HLA-matched  sibling  or
unrelated donor, were often transplanted. Although the number of hematopoietic stem cell
transplantations has decreased during the years it is one treatment option in situations
when imatinib or other tyrosine kinase inhibitor therapy has failed 218.
Despite  the  remarkable  response  rates  of  the  TKI  therapy,  alloHSCT is  still  the  only
curative treatment option. It is however, associated with a significant risk of morbidity and
mortality  and  is  also  eligible  only  to  a  restricted  patient  population:  relatively  young
patients with a HLA-matched donor (reviewed by Goldman) 219.  In  addition,  relapse  of
CML after alloHSCT is affecting approximately 10-30% of CML patients transplanted in
their first chronic phase, and are more common in patients transplanted in advanced
phases of the disease, as reviewed by Dazzi and Fozza 220.  Therefore,  alloHSCT is not a
guarantee of definitive cure, either. Disease relapse after alloHSCT may be treated
immunologically with donor lymphocyte infusions (DLI) with response rates of 60-100%
220. Synergism between DLI and imatinib treatments in managing relapses after alloHSCT
has also been suggested 221.
7. Imatinib resistance
While the majority of CML patients have an excellent response to imatinib treatment,
there are still a proportion of patients who do not achieve optimal or, any kind of response
or lose the earlier achieved response. This implies to treatment resistance. Resistance is
more common in patients with long disease history and advanced phase disease, as initial
responses are usually poorer and the achieved responses are prone to be only transient in
advanced phases of CML (Figure 12). Development of imatinib resistance in Ph
chromosome positive ALL is even more common due to higher level of genetic instability
and more aggressive nature of the disease 222. Imatinib resistance can be classified into
primary or secondary resistance or; according to the type of lacking response: into
hematologic, cytogenetic or molecular resistance. Primary resistance, or refractoriness,
describes a situation where no treatment response of any kind or not a sufficient one has
ever been achieved. If a patient first responds to the treatment but then loses the response
without any obvious reason, secondary, or acquired, resistance may have developed
(reviewed in e.g. 223-225).
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Figure 12 Emergence of primary and secondary hematologic resistance at two years of imatinib
therapy. The frequency of primary resistance is indicated with gray bars and
secondary resistance with black bars. The abbreviations CP, AP and BC denote
chronic phase, accelerated phase and myeloid blast crisis of CML, respectively.
Adapted by permission from Macmillan Publishers Ltd; Leukemia ref. 223, copyright
2004.
The mechanisms that confer CML cell resistance against imatinib can be divided into
BCR-ABL dependent and BCR-ABL independent mechanisms. BCR-ABL dependent
mechanisms include BCR-ABL gene amplification and subsequent overexpression and
point mutations in the region coding for BCR-ABL kinase domain. Resistance
mechanisms independent of BCR-ABL fusion gene are processes involved in drug
transport in and out of the cells or activation of other signaling pathways 223, 225.
7.1. BCR-ABL gene amplification
Earlier cell line studies described the BCR-ABL gene amplification and overexpression as
one mechanism for CML cells to escape the inhibition of imatinib 226-227. In the first report
of 11 patients with acquired imatinib resistance the gene amplification was detected in
three patients 228, but in a larger patient population the amplification was observed in two
patients only 229. The reason why BCR-ABL gene amplification is more commonly seen in
cell lines than clinical samples is not known, but potential toxicity of BCR-ABL
overexpression to the cells has been suggested as one possible explanation 230. Examples
of metaphase cells with an extra copy of BCR-ABL gene are presented in Figure 13.
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Figure 13 BCR-ABL gene amplification through formation of an isochromosome of the Ph
chromosome as observed in standard G-banding (left) or acquisition of additional Ph
chromosome indicated by FISH (right). The Ph chromosomes are indicated with
arrows. Courtesies of Drs Katrin Rapakko and Marja-Leena Väisänen.
7.2. Mutations in the kinase domain of BCR-ABL
Acquired resistance to imatinib is most often due to point mutations in the region coding
for tyrosine kinase domain of BCR-ABL. Primary resistance is less commonly associated
with mutations. The frequency of mutations in imatinib resistant patients varies between
40-90% depending on the disease phase, the methodology applied for the detection and the
criteria used for defining imatinib resistance 229, 231-232.
The mutations can be categorized into two groups depending on their effect in imatinib
binding: 1) those that directly interfere the binding of imatinib resulting in reduced affinity
or steric hindrance and 2) those that alter the three-dimensional structure of BCR-ABL
and destabilize the inactive conformation of BCR-ABL that is required for imatinib
binding 209, 232. The first report of acquired resistance to imatinib detected only a single
point mutation in the kinase domain in six out of nine analyzed patients, a threonine 315
substitution to isoleucine, i.e. T315I 228.  This  mutation  was  later  found to  be  completely
resistant to tyrosine kinase inhibitors available today 233-235. Several other point mutations
have since been described, the total number exceeding 50. However, some mutations are
more  frequently  seen  than  others,  as  15  amino  acid  substitutions  account  for  more  than
85% of the mutations and only seven mutated residues are responsible for 66% of the
reported cases, namely G250, Y253, E255, T315, M351, F359 and H396, as reviewed by
Jane Apperley 225.
The  mutations  tend  to  cluster  into  four  regions  in  the  kinase  domain  (Table  3).  The
first region is the P-loop (amino acids 248-256), a highly conserved region that binds the
ATP phosphate group and also interacts with imatinib. These mutations alter the flexibility
of the P-loop and destabilize the conformation needed for imatinib binding. The second
cluster is directly responsible for the imatinib binding containing the T315 and F317
contact residues. This is followed by the catalytic domain (amino acids 350-363) which
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has a possible role in autoregulation of kinase activity or imatinib binding. The fourth
cluster is located in the activation loop starting with a conserved three amino-acid DFG
motif and ending with APE motif (amino acids 381-407). Mutations in the activation loop
destabilize the kinase to adopt the inactive conformation and therefore favor the active,
open conformation that imatinib is incapable of binding 232, reviewed in 225, 236-238.
Different mutations confer different degrees of resistance. The “gatekeeper” T315I
mutation and the mutations in the P-loop induce complete resistance to imatinib – and in
the case of T315I, also to second generation tyrosine kinase inhibitors – and is an
indication for cessation of imatinib and change of therapy 239-240. Some mutations, on the
other hand, remain biologically sensitive to imatinib and may be overcome by dose
escalation 239. Mutations have also been detected in imatinib-naïve patients using sensitive
allele-specific oligonucleotide-PCR techniques 241-242. These pre-existing mutations
indicate that imatinib itself does not induce the mutations but rather selects the mutated
clones by giving them growth advantage over the non-mutated, imatinib sensitive cells.
However, the mutations detected at low levels may not always explain the clinical
resistance to imatinib, but other mechanisms are contributing to the resistant phenotype
243.
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Table 3. Some point mutations conferring resistance to imatinib and their locations in the
BCR-ABL kinase domain. Adapted from Martinelli et al. 2005 and Baccarani et
al. 2008 244-245 and the references therein.
Imatinib IC50 (nM) Imatinib IC50 (nM)Location in the
kinase domain  BCR-ABL Biochemical inhibition Cellular growth inhibition
Unmutated 300 260-500
 M244V 380 2000
 L248V NA 1500
 G250E 1000 1350-3900
 Q252H NA 1200-2800
 Y253F >5000 3475
 Y253H >5000 >10000
 E255K 2800 4400-8400
 E255V >5000 NA
 F311L 775 480
 T315I >5000 >10000
 F317L 900 810-1500
 M351T 820 930
 E355G NA 400
 F359V 4700 1200
 V379I 800 1630
 H396R 1950 1750
Locations in the kinase domain: P, phosphate binding (P-) loop; IB, imatinib binding region; C, catalytic domain;
A, activation loop. The IC50 values indicate the concentration of imatinib that inhibits the biochemical tyrosine
kinase activity of BCR-ABL and suppresses cell growth in Ph positive cell lines by 50%.
7.3. BCR-ABL independent resistance mechanisms
In addition to direct resistance mechanisms linked to BCR-ABL gene copy number or
structure, indirect mechanisms for resistance are also known. Too low a concentration of
imatinib inside the CML cells may be the cause for inadequate or lacking response.
Intracellular imatinib concentration is partly mediated by drug transporter proteins,
called the ATP-binding cassette (ABC) proteins that transfer different substrates in
(influx) and out (efflux) of the cells 246-248. ABC transporters also have a role in multidrug
resistance (MDR), a phenomenon of simultaneous resistance to various anti-cancer drugs.
Permeability glycoprotein (PGP), encoded by multidrug resistance 1 gene (MDR1, or
ABCB1), is an ABC transporter that is normally involved in excreting toxic agents out of
cells 247.  Imatinib  is  a  substrate  for  PGP  and  therefore  overexpression  of  PGP  may
therefore result in excess transport of imatinib out of the cells conferring intrinsic
resistance to the treatment 249-252. However, conflicting results have also been presented
suggesting not significant contribution of PGP expression to imatinib response 253-254.
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Proteins affecting drug influx, or uptake, may also have an important role in efficacy
of drug treatment. The human organic cation transporter 1 (hOCT-1) is an influx protein
the activity of which is the key mechanism for imatinib uptake into the cells 250, 255. Recent
studies have shown that the hOCT-1 gene expression levels have a wide interpatient
variability and the expression levels may differ significantly between cytogenetic
responders and non-responders 254, 256. The level of hOCT-1 activity has an effect on the
molecular response so that patients with high hOCT-1 activity achieve significantly better
molecular response than those who have low activity. The molecular response in patients
with low hOCT-1 activity is dependent on the imatinib dose so that molecular responses
may be improved with higher doses of imatinib. Determination of hOCT-1 activity level
may therefore identify patients who most probably will have good response to standard
dose of imatinib and patients who may benefit from higher doses of imatinib treatment 257.
In addition to drug transporters, a plasma protein called alpha1 acid glycoprotein
(AGP) is in some reports suggested as one factor contributing to imatinib resistance by
binding to imatinib and preventing the access of the drug into the cells 258-259. However,
this finding has been challenged by other studies indicating that AGP does not abrogate
the antileukemic effect of imatinib 260-261. The role of AGP in imatinib resistance seems to
be somewhat controversial and needs further studies to be clarified.
Loss of BCR-ABL signaling may also be compensated of by activating other kinase
signaling pathways as another mechanism of resistance 262. That is, activation and
overexpression of secondary tyrosine kinases may turn the cells independent of BCR-
ABL. A member of SRC kinase family, the LYN kinase, has been found to be markedly
overexpressed in cell lines and patient samples resistant to imatinib 263-264. Inhibition of
LYN overexpression with short interfering RNA or a SRC kinase inhibitor has triggered
apoptosis in resistant cells providing basis for new therapeutic options 264-265.
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8. Second generation tyrosine kinase inhibitors
Second generation tyrosine kinase inhibitors have been developed for the treatment of
imatinib resistant or intolerant CML or Ph+ ALL. These inhibitors are more potent in
inhibiting BCR-ABL than imatinib and some of them are more flexible in binding to
different BCR-ABL conformations. Some inhibitors also have a broader inhibition target
spectrum which may have additional advantage in growth inhibition through other
signaling pathways 244, 266.
8.1. Dasatinib
Dasatinib (Sprycel®, formerly BMS-354825) is a so called dual tyrosine kinase inhibitor
targeting  ABL,  BCR-ABL,  C-KIT,  PDGFRß,  ephrin  family  kinases  and  also  most  SRC
family kinases (SRC, FGR, FYN HCK, LCK, LYN and YES) 267-268. In vitro, dasatinib is
325 times more potent inhibitor of BCR-ABL than imatinib. It is also capable of binding
to both active and inactive conformations of BCR-ABL and inhibiting most of the
mutations causing resistance to imatinib, with the exception of T315I 234-235, 269-270. Unlike
imatinib, dasatinib does not appear to be a substrate for drug influx protein hOCT-1 271-272.
Whether or not the drug efflux occurs through PGP, has conflicting results 271-273.
Dasatinib induces notable hematologic and cytogenetic responses in patients resistant or
intolerant to imatinib at various phases of CML or Ph+ ALL 274-278. The inhibition of SRC
family kinases has a role in the efficacy of dasatinib in the treatment of blast crisis CML
and Ph+ ALL, since these kinases are activated by BCR-ABL in leukemic cells of
lymphatic origin and involved in development of Ph chromosome positive B-cell ALL 279-
280. Recent studies indicate the efficacy of dasatinib in the treatment of central nervous
system leukemia i.e. neuroleukemia. Neuroleukemia emerges in approximately in 12% of
BCR-ABL positive patients who relapse during imatinib monotherapy 281. As imatinib
passes poorly the blood-brain barrier and has modest activity against neuroleukemia,
dasatinib may be a useful alternative for treatment of these patients 282-284.
8.2. Nilotinib
Nilotinib (Tasigna®, formerly AMN107) is a second generation tyrosine kinase inhibitor
designed to bind the inactive conformation of the BCR-ABL. It  is  20 times more potent
inhibitor than imatinib. Nilotinib is capable of inhibiting the same kinases as imatinib and
clinically relevant BCR-ABL mutant isoforms except T315I 234, 285.  Additionally,  the
cellular uptake of these drugs seems to have a different mechanism as nilotinib influx is
not mediated by hOCT1, or the drug efflux by PGP 255, 286. Nilotinib has proven effective
in imatinib resistant or intolerant patients in chronic and accelerated phases of CML 287-288.
However, the level of response in chronic phase patients may be affected by the baseline
BCR-ABL mutation status or emergence of new mutations, as the less sensitive mutations
are associated with less favorable response 289.
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8.3. Other second generation tyrosine kinase inhibitors
Bosutinib (previously SKI-606), a dual inhibitor for SRC family kinases and ABL, has
demonstrated antiproliferative activity against BCR-ABL positive cell lines in preclinical
studies 290. In contrast to imatinib and dasatinib, it does not have inhibitory activity against
C-KIT or PDGFRs, which may reduce the side effects of the drug. Bosutinib is capable of
binding both active and inactive, as well as intermediate conformations of BCR-ABL and
inhibiting several clinically important mutated forms of BCR-ABL, except T315I 291.
INNO-406 (also known as CNS-9 and NS-187) inhibits primarily ABL and LYN, but
also ARG and FYN kinases being 25-55 times more potent in inhibiting ABL than
imatinib 292. Like other kinase inhibitors presented this far, T315I mutation is resistant
against this drug as well. INNO-406 is a substrate for PGP which reduces its concentration
in the central nervous system to be only one tenth of the concentration in plasma.
However, even this amount of drug seems to be sufficient in inhibiting BCR-ABL positive
neuroleukemia in mouse models making INNO-406 a potential drug against
neuroleukemia 293.
8.4. Resistance against second generation tyrosine kinase inhibitors
Kinase domain point mutations conferring resistance against to the second generation
inhibitors have been studied in various in vitro mutagenesis assays 233, 269, 294-295. Some of
the mutations are the same regardless of the inhibitor, such as T315I, but some are unique
to the inhibitor being used. In general, the spectrum of mutations arising in the presence of
dasatinib or nilotinib is more limited than during imatinib. Nilotinib resistance is mainly
associated to mutations in the P-loop or T315I 294-295, whereas mutations recovering
through dasatinib are often concentrated at contact residues (L248, V299, T315, F317).
Some of the dasatinib resistant mutations remain sensitive to imatinib or nilotinib, such as
V299L, T315A, or F317L/V/I, but T315I has complete resistance against all of the drugs
233-234, 269.
As the use of second generation tyrosine kinase inhibitors after imatinib failure is
getting longer, the clinical resistance has also emerged. Mutations characterized this far
during dasatinib treatment are the ones described in in vitro assays 296-298.  However,  the
selection of compound mutations (i.e. two or more mutations in the same BCR-ABL
molecule) in patients treated sequentially with different inhibitors hampers the
reintroduction of imatinib to treat dasatinib-resistant, imatinib-sensitive mutants. The
compounded mutations can additionally increase the oncogenic potential of the leukemic
cells. This data suggests a role for combined, instead of sequential, use of different
inhibitors 299.
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9. Recommendations for the management of CML: the current review of
the expert panel of the European LeukemiaNet
In 2006, an expert panel appointed by the European LeukemiaNet (ELN) published
recommendations for the CML management based on the literature published since 1998
82. The previous guidelines had been developed in 1998 by the American Society of
Hematology and covered more conventional treatment strategies such as chemotherapy,
interferon-alpha and alloHSCT 300. However, tyrosine kinase inhibitors were not discussed
then.  Therefore,  in  addition  to  updating  results  of  the  interferon-alpha  and  HSCT
treatments  the  panel  of  experts  also  reviewed  the  current  situation  of  tyrosine  kinase
inhibitor (mainly imatinib) therapy based on the present data available.
The expert panel defined parameters for optimal and suboptimal response as well as
for treatment failure. The timelines, by which certain response categories are expected to
be achieved, were also included (Figure 14, Table 4). These categories are nowadays used
for evaluating the level of treatment response and also in selecting patients to new studies
for other treatment modalities.
Figure 14 Timelines for reaching parameters defined for the optimal imatinib (IM) response.
Modified from Baccarani et al 2006 82.
As late responses to imatinib have been also reported 52,  some patients  may achieve  the
response timepoints later than depicted in Figure 14. Still for practical purposes it is useful
to follow the timepoints to be able to evaluate whether the response is satisfactory or not.
This aids to decide whether to continue the current treatment with current dose or to
consider a change in the therapeutic strategy. In situations where the response is not
satisfactory the terms “suboptimal response” and “failure” have been defined. Suboptimal
response means that a patient may still benefit from imatinib treatment, but in the long run
the outcome may not be as good as it is being expected. In failure cases it is evident that
imatinib treatment with the current dose is not anymore appropriate and that the patient
would benefit from other therapeutic options, if available. Imatinib dose escalation,
alloHSCT or investigational treatments are therefore recommended for patients having
failed the standard imatinib treatment. The same options are also worth considering in
patients with suboptimal response. For patients diagnosed with a ”warning sign” listed in
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Table 4, the standard dose of imatinib treatment may not necessarily be sufficient and that
these patients may require more careful monitoring 82.
Since the publication of ELN recommendations, more knowledge on treating imatinib
resistant or intolerant patients have been gained in various studies. The approval and
commence of second generation tyrosine kinase inhibitors has provided more options in
the treatment of CML 218, 225. In addition, newer drugs targeting for T315I inhibition are
currently being studied 301. The ELN recommendations will be updated in the near future
most possibly covering also these treatment modalities.
Table 4. Definition of suboptimal response and treatment failure for CML patients in early
chronic phase treated upfront with 400mg imatinib (IM) daily. Adapted from from
Baccarani et al 2006. 82 and the CML Pocket Card by European LeukemiaNet 302.
Time Suboptimal response Treatment failure Warning signs
Diagnosis N/A N/A High risk score
der(9) deletion
Clonal evolution
in Ph+ cells
+3 months of
IM therapy
Less than CHR No hematologic response  N/A
+6 months Less than partial cytogenetic
response (>35% Ph+ cells)
Less than CHR
No cytogenetic response
N/A
+12 months Less than CCyR Less than partial
cytogenetic response
Less than MMR
+18 months Less than MMR Less than CCyR N/A
Any time Cytogenetic clonal evolution § Loss of CHR * Rise in BCR-ABL
transcript levels
Loss of MMR § Loss of CCyR * * Chromosome
aberrations in
Ph? cells
Kinase domain mutation # Kinase domain mutation ##
N/A, not applicable; CHR, complete hematologic response; CCyR, complete cytogenetic response;
MMR, major molecular response;
§ To be confirmed on two occasions unless associated with loss of CHR or CCyR;
* To be confirmed on two occasions unless associated with progression to accelerated phase/blast
crisis;
* * To be confirmed on two occasions unless associated with loss of CHR or progression to
accelerated phase/blast crisis;
# Low level of insensitivity to imatinib;  ## High level of insensitivity to imatinib
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Aims of the study
The aim of this study was to assess the clinical significance of novel prognostic factors in
the treatment of CML during the advent of tyrosine kinase inhibitors.
In detail, the specific aims of this study were:
1. To compare the efficiency and correlation of molecular cytogenetic (high mitotic index
metaphase-FISH) and molecular genetic (RQ-PCR) techniques in monitoring MRD and
present a model for converting the laboratory specific MRD data to the International Scale
2. To investigate the predictive value of metaphase FISH technique in detecting Ph+
minimal residual cells for CML patients after the allogeneic HSCT
3. To determine the impact of der(9) deletions in the disease course and treatment
response after allogeneic HSCT
4. To study whether bone marrow lymphocytosis is a prognostic marker for cytogenetic or
molecular response to imatinib treatment
5. To define the mutation spectrum BCR-ABL kinase domain in Finnish and Norwegian
CML patients resistant to imatinib.
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Materials and methods
1. Patients
The Study I comparing different follow-up techniques included altogether 96 CML
patients whose MRD level was investigated with various techniques after alloHSCT or
during imatinib treatment. The patients had been treated in Helsinki University Central
Hospital or in Turku University Central Hospital.
Both Studies II and III consisted of a total of 102 (II) or 110 (III) CML patients who
underwent an alloHSCT at Helsinki University Central Hospital between the years 1990
and 2003. Bone marrow aspirates were taken after alloHSCT for follow-up studies (II) or
before transplantation for determination of der(9) deletion status (III).
The patient population investigated in Study IV consisted of a total of 37 adult CML
patients  treated  in  the  Helsinki  University  Central  Hospital.  All  the  patients  were  in
chronic phase and received standard dose of imatinib as a first-line therapy or as a second-
line treatment after hydroxyurea or interferon (7 patients).
The Study V characterizing the BCR-ABL mutation spectrum in two Nordic CML
patient populations composed of a total of 77 CML patients (49 Norwegian, 28 Finnish
patients) resistant to imatinib. The classification of imatinib primary and secondary
resistance was defined after adjusted recommendations of European LeukemiaNet 82 and
is shown in Table 5.
Table 5. Definitions for imatinib primary and secondary resistance in Study V.
Resistance type Definition
Primary, complete No cytogenetic response at 6 months (>95% Ph+ cells), or
No partial cytogenetic response at >12 months of therapy
(>65% Ph+ cells in bone marrow)
Primary, partial Partial, but not complete cytogenetic response at 12 months of therapy
(1-65% Ph+ cells in bone marrow)
Secondary Loss of complete or major cytogenetic response;
Loss of hematologic response, or progression to accelerated phase or
blast crisis
Other Does not fulfill any of the criteria above
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2. Methods
2.1. Cell culture (I-V)
Bone marrow aspirates were taken for cytogenetic (conventional G-banding or FISH)
analyses. Cell culturing was performed according to standard methods as previously
described 179. Briefly, bone marrow cells (20x106 nucleated cells) were cultured overnight
for 17 h at 37oC in 5% CO2 incubator in 50 ml flasks within 10 ml culture medium
including 2 ml of fetal calf serum and of 8 ml RPMI medium containing 1% L-glutamine,
1000 IU streptomycin and 1000 IU penicillin (Gibco, Invitrogen Corporation). An
elongated 17 hour exposure to colcemid (0.1 ?g/ml) was used to obtain maximum number
of metaphases. Harvesting was done with hypotonic solution (0.075 M KCl, 20 min
+37?C) and fixation with freshly prepared methanol: acetic acid fixative (3:1). The
chromosome preparations were done by dropping the cell suspension onto warm
microscope slides in a humidified (50%) conditions. The sufficient spreading of the
chromosomes was checked under a phase microscope and the technique of making the
preparations was adjusted if needed. Metaphase-FISH preparations were done in the same
way as in standard cytogenetics but the cell density on the slides was higher than in
preparations used for standard karyotyping.
2.2. Conventional cytogenetic analysis (I-V)
Conventional karyotyping of the CML samples was performed with standard G- banding
by using trypsin – Giemsa technique 303. A total of 20 mitotic cells were analyzed by using
the Ikaros Karyotyping System software (MetaSystems GmbH, Altlussheim, Germany).
The karyotypes were assigned according to the international system for human cytogenetic
nomenclature 304.
2.3. Fluorescence in situ hybridization (FISH) (I-IV)
The FISH probes used in the studies
Whole chromosome painting probe specific to chromosome 22 or locus-specific probe
mixture specific for BCR and ABL genes were used for detection of Ph positive minimal
residual cells (I, II, IV) or for identification of der(9) deletions (III). Chromosome 22
painting probe was a commercial, fluorescein isothiocyanate (FITC) labeled product
(Cambio Ltd, Cambridge, UK). The locus-specific LSI® BCR-ABL Dual Color Dual
Fusion Translocation Probe was labeled with Spectrum Green™ (BCR) and Spectrum
Orange  ™  (ABL)  and  purchased  from  Vysis  (Downers  Grove,  IL,  USA).  Additional
probes were used for complementing the interpretation of ambiguous results (III). These
were LSI® 9q34 labeled with Spectrum Aqua™ (Vysis), rhodamine/ dGreen –labeled
t(9;22) D-FISH™ Translocation DNA Probe and digoxigenin- and biotin-labeled M-
bcr/abl Translocation DNA probe that was used for the exclusive detection of BCR-ABL
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fusion (Appligene Oncor®, Qbiogene Illkirch Cedex, France). The hybridizations and
post-hybridization washes were performed according to manufacturers’ instructions or
with modifications listed below.
Slide pretreatments (I, III-IV)
Fresh cytogenetic preparations made from the stored cell suspensions on previous day
were pre-treated by incubating the slides in 0.01 N HCl containing 20 ?l pepsin (20
mg/ml) for three minutes at +37?C, rinsing in PBS for three minutes and then proceeding
according to the FISH protocol.
The pretreatment of archival G-banded preparations was performed as described 305,
with minor modifications. Briefly, Entellan (Merck, Darmstadt, Germany) mounted slides
were soaked in toluene for 3 to 7 days at room temperature until the cover slips
spontaneously detached. The slides were rinsed in fresh toluene and immersed in 100%,
96% and 70% ethanol series, 5 minutes each, and air dried. After drying the slides were
fixed  in  a  cold  (+4?C) buffered formaldehyde-acetone fixative (10 mg Na2HPO4,  15  ml
distilled water, 33.75 ml acetone and 12.5 ml formaldehyde) for one minute, washed under
running cold tap water for two minutes and air dried again. Then the slides were incubated
in 2xSSC/0.2% Tween 20 solution for 2x 15 minutes at +42?C, washed under running
warm (35-40?C)  tap  water  for  two  minutes,  and  air  dried  gently.  Then  the  slides  were
incubated in 0.01 N HCl/ 250 ?l pepsin (20 mg/ml) pepsin for three minutes at +37?C and
then rinsed in PBS for another three minutes.
FISH protocol for locus-specific probes
The protocol used for locus-specific FISH was adopted from previous works 306-307. The
slides were incubated in a coplin jar containing 2x SSC at +70?C for 30 minutes in a water
bath.  The  coplin  jar  was  taken  out  from  the  water  bath  and  let  cool  down  at  room
temperature for 20 minutes, after which the slides were transferred to 0.1x SSC for one
minute at room temperature. The slides were denatured in 0.07N NaOH for one minute at
room temperature. After the denaturation the slides were incubated in cold (+4?C) 0.1x
SSC and 2x SSC for one minute each and finally dehydrated in 70%, 85% and 100%
ethanol series, one minute each, and air dried. The denaturation of the probe mixture,
hybridization and post-hybridization washes were performed according to the
manufacturers' instructions. The slides were mounted counterstained with Vectashield®
mounting medium with DAPI (4’,6-diamidino-2-phenylindole-dihydrochroride)
counterstain (Vector laboratories, Inc. Burlingame, CA, USA).
Analysis
For minimal residual disease analysis (MRD), a median of 792 (I) 996 (II), and 525 (IV)
mitotic cells were analyzed. In study III, the number of analyzed metaphases was lower
(median 31), since der(9) deletion is regarded as occurring simultaneously to Ph
translocation, not as a secondary event and therefore is not assessed as an MRD setting.
The normal and derivative chromosomes 9 were recognized both by the normal red ABL
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signal and the fusion signal (or abnormal variations thereof) in 9q34, and by strongly
fluorescent heterochromatin block in 9q near the centromeric region. Image acquisition
and analysis was performed using a Zeiss Axioplan 2 imaging microscope and the ISIS
digital image analysis software (MetaSystems GmbH, Altlussheim, Germany) or a Leica
DMRB microscope and the Cytovision software (Newcastle Upon Tyne, UK).
2.4. Sample preparation, RNA extraction and the reverse transcription reaction (I,
IV-V)
Total RNA was extracted from mononuclear cells from bone marrow or peripheral blood
samples. Bone marrow or peripheral blood samples were collected to cell preparation
tubes (BD Vacutainer® CPT™, Becton Dickinson New Jersey, USA) that enable the
separation of mononuclear cells by centrifugation. The blood volume collected was 2x 8
ml and bone marrow volume 2x 4 ml, respectively. Centrifugation (1600xg, 30 minutes at
room temperature) was performed within 30 minutes of sample collection to segregate
mononuclear cells from granulocytes including eosinophils containing eosinophil derived
neurotoxin, which is the major source of leukocyte RNase activity 308. This enabled
standard sample shipment without significant loss in RNA yield. A total of 6-10 x106
mononuclear cells were used for RNA extraction using RNeasy Mini Kit (Qiagen, Hilden
Germany) according to manufacturer’s instructions. The reverse transcription reaction was
performed according to standardized protocols published by the EAC program 184. One
microgram of total RNA was reverse transcribed using 100 U of MMLV enzyme
(Amersham Biosciences, Little Chalfont, UK) with 25 ?M of random hexamers
(Amersham Biosciences) in a final volume of 20 ?l.  After  the  reaction  the  cDNA  was
diluted with 30 ?l of water.
2.5. Real time quantitative polymerase chain reaction (I, IV-V)
Real time quantitative polymerase chain reaction (RQ-PCR) assays for detection of
residual BCR-ABL transcripts, including the primer and probe sequences used in the
reactions were performed according to the standardized protocols of the EAC program 184.
Five micro liters corresponding to 100 ng of cDNA was used in the real time quantitative
PCR reactions. The 1x Taqman® Universal Master Mix reagent (Applied Biosystems,
Foster City, USA), 300 nM of each primer and 200nM of Taqman probe were used in the
final  reaction  volume  of  25 ?l. The PCR reactions were performed on an ABI 7700
platform  (Applied  Biosystems).  The  reactions  consisted  of  50  amplification  cycles.  The
baseline was set between cycles 3-15 and the threshold at 0.1 within the exponential
growth region of the amplification curve.
The beta glucuronidase (GUS)  was  used  as  the  reference  gene  to  normalize  the
variability of the RNA quality and the reverse transcription reaction efficiencies between
different samples 185. Absolute quantification of the transcripts was obtained using
commercial plasmid standards (Ipsogen, Marseille, France). For follow-up samples the
log10-reduction value as compared to the median diagnostic baseline was calculated using
the formula: 0-[log10(median of diagnostic BCR-ABL/GUS ratio) – log10(follow-up BCR-
ABL/GUS ratio)]. Logarithmic reduction of the residual disease was calculated against the
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laboratory median BCR-ABL/GUS value of a total of 27 (peripheral blood, median ratio
0.35) and 32 (bone marrow, median ratio 0.34) pretreatment samples, respectively.
Logarithmic decline in respect to the median values of EAC were also calculated as
indicated in the article of Gabert et al. (0.22 for peripheral blood and 0.12 for bone
marrow, respectively) 184. The level of sensitivity of the PCR assay was calculated in
samples that had undetectable levels of residual BCR-ABL transcripts.
2.6. Bone marrow morphological analysis and immunophenotyping (IV)
Bone marrow aspirate samples were taken according to normal clinical treatment
protocols usually every three months during imatinib therapy. Two representative smear
preparations from the samples were stained with May-Grünwald-Giemsa staining. One
hundred cells were calculated from four microscope fields per preparation, i.e. a total of
eight fields (800 cells) were evaluated in a brightfield microscope equipped with 100x
objective and 10x oculars. The percentages of lymphocytes were based on the mean
number of lymphocytes in these eight fields. The upper limit for normal bone marrow
lymphocyte count was regarded as 24% of the nucleated cells 309.
Immunophenotyping was done using a panel of monoclonal antibodies against
following cell surface antigens: CD3, CD4, CD5, CD7 (eBioscience, San Diego, CA,
USA), CD8, CD11c, CD14, CD16, CD19, CD20, CD25, CD34, CD38, CD16/56, CD45,
CD56, CD57, CD117 (DAKO, Glostrup, Denmark), CD133 (Miltenyi Biotech, Bergisch
Gladbach, Germany), CD206, TCR-?/ß, TCR-???, and kappa and lambda light chains
(DAKO). Dendritic cells were analyzed using antigens CD303, CD141 and CD1c
identifying plasmacytoid dendritic cells, type-1 myeloid dendritic cells, and type-2
myeloid dendritic cells with the blood dendritic cell enumeration kit (Miltenyi Biotech).
FoxP3 antibody (clone PCH101, eBioscience) and CD25 staining were used for
characterization of regulatory T-cells. Five samples from CML patients taken at the time
of diagnosis were used as controls. The flow cytometric analysis was performed using the
BD FACSCalibur™ (BD Biosciences, San Jose, CA USA) system. A total of 1-5 x 105 of
cells were analyzed depending of the cell type. The data was analyzed with Winlist™ 6.0
(Verity Software House, Topsham, ME, USA) or FACSDiva™ 4.1 (BD Biosciences)
programs. The control values for normal bone marrow B cell compartment were obtained
from a study performed by BIOMED-1 Concerted Action 310.
2.7. BCR-ABL kinase domain mutation analysis (V)
Total RNA was extracted from the mononuclear cells of peripheral blood or bone marrow
samples and reverse transcribed to cDNA according to EAC protocols as described in
chapter 4.2.4., without diluting the cDNA preparation with 30 ?l of water. BCR-ABL
fusion transcript was first amplified from 2 - 5 ?l of cDNA with primers (nM) indicated in
Table 6 using Phusion™ DNA polymerase with GC Buffer (Finnzymes, Espoo, Finland).
After agarose gel electrophoresis the PCR product was diluted (1:1000 or 1:100)
depending on the intensity of the amplified BCR-ABL fragment  on  the  gel  and  on  the
absolute  number  of  BCR-ABL copies  in  simultaneous  RQ-PCR assay.  The  diluted  PCR
product was then used as a template for three partially overlapping nested/seminested PCR
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reactions  (fragments  B,  C  and  D,  Table  6)  covering  the  kinase  domain  (amino  acid
residues 209-498). These PCR products were then purified (QIAquick PCR purification
kit, Qiagen, Hilden Germany) and sequenced in both directions using the same primers. If
more than one band of the expected size was observed on the gel, both bands were cut out
of the gel, purified separately with QIAquick Gel extraction kit (Qiagen, Hilden Germany)
and sequenced in both directions. The Norwegian CML patient samples were analyzed as
described by Gruber et al. 2006 311 and by further expanding the region with another set of
primers. In addition, single samples were cloned into a pCR 2.1 vector.
Table 6. The primer sequences, expected amplicon size, primer binding sites and references
for primers used in the KD mutation screening assays of Finnish imatinib resistant
CML patients.
PCR
reactions
Amplicon
size bp,
(b3a2 / b2a2)
Primer binding
site
Primer sequences (5´- 3´) Ref.
BCR-ABL 1579 / 1502 BCR exon 13
ABL exon 9/10
TGACCAACTCGTGTGTGAAACTC
TCCACTTCGTCTGAGATACTGGATT
312
Nested
PCR
B 393 ABL ex 4-6 CATCATTCAACGTGTGCCGACGG
GTTGCACTCCCTCAGGTAGTC
313
C 492 ABL ex 4-7 GAAGAAATACAGCCTGACGGTG
CGTCGGACTTGATGGAGAA
313
D 483 ABL ex 6-9 GATCTCGTCAGCCATGGAGT
reverse as in BCR-ABL PCR
2.8. Statistical calculations
Correlations between different follow-up analyses were defined by calculating the
Spearman rank order correlation (rs). The statistical significance of differences was
assessed with Mann-Whitney U or Kruskall-Wallis nonparametric tests for continuous
variables  and  with  Fisher’s  Exact  test  for  categorical  variables.  The  results  were
considered statistically significant at p?0.05 (I, IV).
In Study III, overall survival was defined from date of transplantation until date of
death or of last follow-up. Leukemia-free survival was defined from date of
transplantation until date of death or relapse, or date of last follow-up. Relapse-free time
was defined from date of transplantation until date of relapse or date of last follow-up.
Differences in diagnostic or pre-transplant characteristics were assessed with the Fisher's
Exact Mann-Whitney U tests. Survival calculations were based on Kaplan-Meier
estimates. Differences in significance were tested with the log-rank test. Survival data
from the two groups of patients were also used for constructing a Cox proportional hazard
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model. Variables considered were der(9) deletion status, age at the time of transplantation,
patient sex, percentage of blasts in peripheral blood and platelet count at the time of
diagnosis, donor-recipient sex mismatch (female to male), donor type (sibling or matched
unrelated), disease stage at the time of transplantation and time from diagnosis to
transplantation. Only the last three variables had a p value less than 0.20 in univariate
analyses and were included in the multivariate analysis along with the deletion status. A
backward stepping procedure was used to derive the most significant model. The hazard
ratio of the deletion status as a univariate analysis was compared to the hazard ratios
following adjustment for the most significant model. All calculations were done using
SPSS software (versions 11.0, 14.0 and 14.0.1 for Windows, SPSS Inc., Chicago, IL,
USA).
3. Ethical permissions
Approvals for patient sample collection and laboratory analysis were obtained from
HUCH ethical committee (Dnro 361/E5/02 and 49/E5/07). Many patients were treated
according to clinical drug study protocols with appropriate competent authority and ethics
committee approvals.
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Results
1. Assessment of minimal residual disease in CML (I, II)
1.1. Comparison of molecular cytogenetic and molecular genetic techniques in
detecting minimal residual disease (I)
A total of 291 bone marrow high-mitotic index metaphase FISH assays, 173 peripheral
blood and 222 bone marrow RQ-PCR analyses were performed. The total number of RQ-
PCR tests also included 27 peripheral blood and 32 bone marrow samples that were taken
at the time of diagnosis. The median number of analyzed metaphases in FISH analyses
was 540, and for the actual MRD setting (none or <1% of residual cells) the median was
792  mitotic  cells  (Table  7).  Peripheral  blood  and  bone  marrow  RQ-PCR  assays  gave  a
positive result in a total of 101 in 118 follow-up samples, respectively. The majority of the
RQ-PCR negative samples were taken from patients who had undergone alloHSCT.
The  RQ-PCR  samples  taken  at  the  time  of  diagnosis  were  used  for  determining  the
median diagnostic BCR-ABL/GUS ratio that for peripheral blood samples was 35% (27
samples) and for bone marrow 34% (32 samples). No statistical difference was observed
between the sample types. Likewise, no difference in the relation of bone marrow BCR-
ABL/GUS transcript levels and prognostic factors such as Sokal or Hasford scores, bone
marrow of peripheral blood cell counts, or imatinib response (when applicable), was
observed.
Table 7. Metaphase FISH analyses in 291 follow-up samples of 82 patients in Study I. The
median number of analyzed metaphases in samples with none or <1% of residual
cells (MRD setting) is marked with an asterisk.
Cytogenetic results
(% of Ph positive cells)
Number of samples (%) Median number of analyzed
metaphases (range)
0% 167 (57%) 804 (6-1300)
<1% 35 (12%) 792 (178-1028)
1-34.9% 48 (17%) 200 (41-1013)
35-95% 24 (8%) 50 (20-360)
>95% 17 (6%) 40 (10-102)
Total 291 (100%) 540 (6-1300)
MRD* 202 (62%) 792* (6-1300)
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The Spearman rank order correlation coefficient (rs) between concurrent FISH and
peripheral blood RQ-PCR MRD positive sample pairs (n=62) was 0.769 (p<0.001).
Simultaneous FISH and bone marrow RQ-PCR analyses (altogether 68 positive samples)
also correlated well with each other (rs 0.91, p<0.001). Peripheral blood RQ-PCR still
detected BCR-ABL fusion transcripts in 30 and bone marrow RQ-PCR in 44 samples that
according to simultaneous metaphase FISH analyses were considered representing
complete cytogenetic response. The logarithmic decline from the median diagnostic
baseline in these samples was in most cases more than 2.3 log units in peripheral blood
and >2.6 log units in bone marrow samples (Figure 15). No metaphase FISH positive, RQ-
PCR negative cases were detected.
Figure 15 The correlation of positive follow-up samples between bone marrow metaphase FISH
and RQ-PCR assays performed from peripheral blood (gray line and circles) or bone
marrow samples (dashed black line and triangles) in Study I. The horizontal lines
represent the amount of residual disease detected by RQ-PCR in metaphase FISH
negative samples (blood with gray and bone marrow with black color, respectively).
Concurrent peripheral blood and bone marrow RQ-PCR data was available from 104
sample pairs, altogether 66 of them being positive with a correlation of 0.82 (p<0.001).
Both samples were negative in 25 cases, whereas 13 sample pairs gave discordant results.
In ten peripheral blood samples that were RQ-PCR negative the corresponding bone
marrow RQ-PCR sample still detected residual transcripts and in three samples the
situation was the other way round. The level of MRD detected was between -3 and -4 log
units indicating only marginal residual disease. The majority of samples had undetectable
level of BCR-ABL transcripts with RQ-PCR, were from patients that had undergone
alloHSCT.
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1.2. Model for converting laboratory specific data to the International Scale (I)
The  samples  taken  at  the  time  of  CML  diagnosis  were  analyzed  with  RQ-PCR.  The
median values of the BCR-ABL/GUS transcript ratio (35% for peripheral blood and 34%
for bone marrow) were used for converting the RQ-PCR data to the International Scale.
The baseline values were set as 35% and 34% and a three-log reduction accordingly to
0.035% and 0.034% for peripheral blood and bone marrow, respectively. This produced a
conversion factor of 2.86 for both sample types. The data was also compared to the
International Scale by using distinct standardization samples prepared at the RQ-PCR
reference laboratory in Mannheim. Mannheim laboratory also calculated the preliminary
conversion factor to the International Scale, which was 1.8446.
In addition, the data obtained from bone marrow high mitotic index metaphase FISH
was used for building a regression model for predicting the frequency of Ph chromosome
positive mitotic cells in bone marrow based on the values on the International Scale. The
values based on the analysis are indicated in Table 8.
Table 8. Correspondence of the International Scale to the percentage of Ph positive cells in
bone marrow as assessed by FISH. The percentages of Ph positive cells were
calculated according to the equation shown in Study I Supplementary data, Figure
3.
International Scale Ph positive cells in bonemarrow by metaphase FISH
Log % %
0.0 100 81.1
-0.3 50 46.8
-1.0 10 13.0
-1.3 5 7.5
-2.0 1 2.1
-2.3 0.5 1.2
-3.0 0.1 0.33
-3.3 0.05 0.19
-4.0 0.01 0.05
1.3. The effect of sample source on BCR-ABL transcript levels
The transcript levels were very similar in bone marrow and peripheral blood. However,
when individual patient MRD values of concurrent blood or bone marrow RQ-PCR assays
were compared, two groups of patients appeared with a consistent difference between the
blood or bone marrow values in repeated follow-up samples. One group had consistently
higher MRD levels in peripheral blood than in the bone marrow and the other group had
the opposite situation (Figure 16). Similar results were found when the peripheral blood
RQ-PCR data was compared to bone marrow FISH data, reflecting a true difference in
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relative tumor burden. In a few patients, the difference was substantial (>2 logs, data not
shown), but for most patients it was in the range of ±0.5 log.
Figure 16 Relation of bone marrow and peripheral blood BCR-ABL/GUS transcript ratios in
four representative patients in Study I.
1.4. Minimal residual disease after allogeneic hematopoietic stem cell transplantation
(II)
A total of 361 bone marrow follow-up samples of 102 transplanted CML patients were
analyzed. The overall follow-up time of the patients was 2-111 months, median 28 months
after transplantation. A median of 996 (range 10 – 2148) mitotic cells were analyzed using
metaphase FISH technique. Residual cells were observed in altogether 33 patients (32%)
after alloHSCT. Seventeen (52%) of them had less than one percent of Ph positive residual
cells, which became undetectable in 12 (71%) of them without any intervention except
withdrawal of immunosuppression as routinely scheduled. Nineteen patients experienced
cytogenetic relapse during the first year after alloHSCT. For further description, the
patients were divided in two groups depending on whether minimal residual cells were
seen during the first four months after alloHSCT or not.
Residual disease detected within the first four months after alloHSCT
Residual cells were detected in single or consecutive samples during the first four months
after transplantation in 18 patients (17.6%). In 13 of them cells were detected at
frequencies below 1%. During the first year after transplantation the residual cells became
undetectable without any intervention in eight patients. In five patients residual cells were
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first  observed  at  a  frequency  of  less  than  1%,  but  after  four  months  the  number  of
abnormal cells increased beyond the frequency of 1% indicating metaphase-FISH relapse.
Five patients had more than 1% of residual cells when first detected.
Residual cells were detected from 3 weeks to 8 months (median 2.5) months prior to
detection of cytogenetic relapse evident by conventional karyotyping. The relapsed
patients were treated with interferon-alpha, DLI, chemotherapy and with imatinib.
No minimal residual cells detected during the first four months after alloHSCT
In the other group of 84 patients no residual cells were detected in the bone marrow
samples during the first four months after alloHSCT. Most of the patients (altogether 69,
67.6% of the total patient population) achieved and also remained in complete cytogenetic
and hematologic remission. No minimal residual cells were detected in their samples at
any time of the follow-up.
Residual cells emerging later than four months after transplantation were observed in
15 patients (14.7%). Four patients showed less than 1% of Ph positive cells at 12 months
after  alloHSCT  in  one  or  more  samples.  In  these  patients  the  residual  cells  disappeared
when immunosuppression was discontinued as routinely scheduled, and the patients
stayed in complete remission 27-111 months after transplantation.
In nine patients no residual cells were detected in samples preceding FISH or
cytogenetic relapse, which was evident within one year after alloHSCT. The therapy
administered to the relapsed patients was discontinuation of immunosuppression,
administration of interferon, imatinib or DLI. Two patients (2.4%) relapsed late, 54 and 59
months after transplantation, respectively.
2. The frequency and influence of der(9) deletions on the outcome of
allogeneic hematopoietic stem cell transplantation (III)
Deletions in derivative chromosome 9 were found in altogether 18 patients (15% of all
patients). In 11 patients the deletions spanned both to 5´ABL and 3´BCR sequences in
der(9). The deletion of 5´ABL region was observed in six patients and the rare deletion of
3´BCR region only in one CML patient. In each patient with a deletion in der(9), the
deletion could be seen in every Ph positive metaphase. If a relapse sample was available
for  FISH  studies,  it  gave  congruent  results  with  the  diagnostic  or  pre-transplantation
sample: no deletion in der(9) was seen in relapse if the deletion had not been identified in
earlier samples. These findings give support to the hypothesis that the deletions are
probably not related to disease progression. No deletions were observed in any of the nine
patients with variant Ph translocation. The Ph negative, BCR-ABL positive patient in the
current cohort showed two fluorescent signals when studied with the 9q34 probe, one in
chromosome 9q, the other in chromosome 22, as a sign of insertion without deletion.
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Disease characteristics at diagnosis and before transplantation according to deletion
status
No clinically significant differences were observed at the time of diagnosis in patients
with or without deletions. Before alloHSCT, the transplantation outcome-related
prognostic variables, like the EBMT risk score, were evenly distributed between patients
with or without deletions. However, the cytogenetic responses to an interferon-alpha -
containing therapy tended to be poorer in patients with deletions, though the difference
was not statistically significant.
Transplantation outcome by deletion status
As the median follow-up time was not different in patients with deletions or without
deletions, the comparisons between deletion status groups are relevant. The total relapse
rate during follow-up was of the same frequency in patients with or without deletions
(17% and 22%, respectively, p=0.76). Likewise, the Kaplan-Meyer outcome estimates for
overall survival, transplant-related mortality, leukemia-free survival and relapse-free time
were nearly identical in the deletion status groups (Figure 17). Multivariate analysis with a
backward stepping model and using known factors associated with overall survival
resulted  in  the  elimination  of  the  deletion  status  at  the  first  step,  indicating  that  it  was
affecting the survival the least in the model. When the deletion status was forced in the
multivariate model along with significant prognostic factors (donor type, disease stage at
the time of transplantation and time from diagnosis to transplantation) the adjusted hazard
ratio for deletion status was 0.75 (95% confidence interval 0.31-1.83) as compared to
univariate hazard ratio of 0.85 (0.36-2.04).
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Figure 17 Transplantation outcome by deletion status in Study III. (A) Overall survival, (B)
transplant-related mortality, (C) leukemia-free survival and (D) cumulative relapse
rate by der(9) deletion status.
3. Factors associated with different responses during imatinib treatment
(IV, V)
3.1. Favorable: bone marrow lymphocytosis predicts optimal response to imatinib
(IV)
A total of 37 CML patients in chronic phase were enrolled in this study In 18 patients the
therapy response was regarded as optimal, in seven patients as suboptimal and in eight
patients as failure. Four patients were not classifiable in any of the above mentioned
groups due to too short a follow-up time. The median follow-up time during imatinib
therapy was 18 months. No statistically significant differences were observed between the
response groups and blood cell counts, spleen size or patient age at the time of diagnosis.
The median follow-up time during imatinib therapy and the mean doses of imatinib did
not differ between various response groups.
BA
C D
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Morphological changes in bone marrow aspirates
All patients, except one failure patient, achieved complete hematological response by 6
months of imatinib treatment. In some patients, increased amounts of lymphocytes were
observed in follow-up samples during imatinib therapy. The morphology of lymphocytes
varied in size and shape and also included immature forms. At the time of diagnosis none
of the patients had increased amounts of lymphocytes in the bone marrow as the mean
percentage of lymphocytes was 3%. After three months of imatinib therapy, the bone
marrow cellularity had decreased and was normal in 36/37 patients. The median
percentage of lymphocytes was 17%, but there was a marked variability between different
patients. Two groups in relation to the amount of lymphocytes were distinguished: patients
with clearly increased lymphocyte counts and patients with normal lymphocyte counts.
Flow cytometric analyses
The immunophenotyping of the bone marrow lymphocytes was assessed with flow
cytometry. Based on immunophenotyping, the lymphocytes detected in optimally
responding patients showed no expansion of only one cell type but consisted of T-, B-, and
NK cell populations as in normal samples. At the time of diagnosis, the CML patients had
decreased number of B cells in the bone marrow when compared to normal control values
(7% of lymphocytes vs. 20% and no immature or maturating forms were detected. Patients
with suboptimal or failed response to imatinib also had decreased number of B cells in the
bone marrow, whereas patients having optimal response and bone marrow lymphocytosis
had normal or increased amounts of B cells and immature forms were also detectable. In
mature B cells the kappa and lambda light chain expression was polyclonal. In T cells the
CD4/CD8  ratio  was  normal  and  the  proportion  of  regulatory  T  cells  (Tregs)  in  bone
marrow was comparable in different groups. The number of myeloid and plasmacytoid
dendritic cells was decreased in samples taken at the time of diagnosis and in poorly
responding patients, whereas the numbers were comparable to normal levels in patients
with optimal response to imatinib treatment. The flow cytometric data is presented in
Table 9.
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Table 9. The flow cytometric data on immunophenotyping the bone marrow samples of 21
CML patients in Study IV. The data presented comprises of samples taken at a
median of 12 months of imatinib therapy (range 6-30 months for optimal and 3-24
months for suboptimal response or treatment failure, respectively).
Diagnostic phase
samples (n=5)
Optimal
response (n=11)
Suboptimal response/
failure (n=5)
Median % (range) Median % (range) Median % (range)
Total BM WBC count * 181 (149-314) 31 (5-51) 23 (7-83)
Lymphocytes 2 (1-3) 18 (5-22) 11 (5-18)
Monocytes 2 (0.3-5) 5 (4-8) 4 (2-9)
Granulopoietic cells 89 (85-95) 66 (55-75) 74 (60-84)
Erythropoietic cells 1 (1-5) 12 (5-14) 10 (5-16)
BM lymphocytes
T cells (CD3pos) 61 (51-72) 55 (32-65) 68 (50-84)
NK cells
(CD3negCD16/56pos) 15 (5-34) 15 (7-28) 9 (6-17)
B cells (CD19) 6 (2-13) 24 (14-30) 15 (4-37)
T cells
CD8pos 39 (27-63) 43 (35-56) 40 (29-57)
CD4pos 52 (31-70) 47 (33-59) 55 (33-67)
CD57pos 29 (10-46) 13 (6-29) 13 (7-31)
TCR ?/ß 93 (72-98) 96 (82-99) 92 (75-97)
TCR ?/? 7 (2-28) 4 (1-18) 8 (3-24)
Treg 1 (1-4) 1 (1-2) 1 (0.2-2)
B cells
Mature 96 (80-100) 71 (46-86) 80 (50-100)
Maturating 0 (0-15) 24 (6-42) 14 (0-33)
Immature 0 (0-0) 5 (3-15) 2 (0-8)
Kappa 54 (45-61) 60 (48-62) 54 (44-63)
Lambda 39 (31-48) 39 (36-48) 43 (39-53)
Dendritic cells
(of total WBCs)
Myeloid, type1 0.00 (0-0.03) 0.11 (0.10-0.19) 0.09 (0.07-0.14)
Myeloid, type2 0.00 (0-0) 0.02 (0.02-0.04) 0.01 (0-0.02)
Plasmacytoid 0.01 (0-0.03) 0.11 (0.09-0.27) 0.11 (0.05-0.20)
*) Total BM WBC count is marked as absolute numbers (109/l); the other variables are reported as
percentages. BM, bone marrow; WBC, white blood cells; TCR ?/ß, T cell receptor alpha/ beta
chain; TCR ?/?, T cell receptor gamma/delta chain; Treg, regulatory T cell.
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Predictive value of lymphocytosis to cytogenetic and molecular responses
Patients having either optimal, suboptimal or failure response to imatinib treatment had
different amounts of bone marrow lymphocytes at three months and six months of therapy
the optimal responders having a median of 25% and 26% of lymphocytes compared to
suboptimal and failure patients with 19% and 11%, and 10% and 11% at three and six
months of therapy, respectively (p<0.05). To exclude random variations in lymphocyte
counts, only patients who had had increased lymphocyte count in at least two bone
marrow samples during 12 months of follow-up, were regarded as patients with
lymphocytosis. With this specification, 56, 29 and 0% of patients with optimal,
suboptimal and failure imatinib response had detectable bone marrow lymphocytosis,
respectively (p<0.005, Figure 18).
Prognostically bone marrow lymphocytosis detected in three months of imatinib
therapy indicated the probabilities of 83% for the patients to reach CCyR in 12 months
and  89%  for  MMR  in  18  months  of  treatment,  respectively.  If  a  patient  had  reached  at
least partial cytogenetic response (?35% of Ph+ cells) in three months and simultaneously
exhibited bone marrow lymphocytosis, the probability of reaching MMR in 18 months
was 100% (p<0.001). The absence of both of these factors also resulted in the lack of
MMR in 18 months of therapy in all patients. The positive predictive values of more
established prognostic parameters, such as Sokal or Hasford scores, were clearly lower
and not significant.
Figure 18 The distribution of bone marrow lymphocytosis among different response groups to
imatinib treatment in Study IV.
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3.2. Unfavorable: BCR-ABL kinase domain mutations in patients resistant to
imatinib (V)
Point mutations in the BCR-ABL kinase domain were found in a total of 32 out of 77
(42%) CML patients. Altogether 18 different mutations were detected, four patients
having two point mutations (Figure 19). All the mutations were located in the amino acid
residues previously known to confer resistance to imatinib. The most common mutations
were M351T and G250E, the first one being observed seven times, the other in five cases.
The same residue had a different mutation in two cases: E255K and E255V (both in the
same patient), and F359V and F359I (three patients, two having a F359V and one patient
with a F359I). The P-loop and the catalytic domain were the most frequently mutated
regions  in  the  kinase  domain,  as  67%  of  the  detected  mutations  localized  into  these
regions, respectively. No patients with the multiresistent T315I mutation were detected.
Figure 19  The spectrum of point mutations detected in the BCR-ABL kinase domain in imatinib
resistant CML patients in Study V. The black stars represent patients with the
particular mutations. The smaller grey stars indicate the double mutations detected
simultaneously with some other mutation. P, phosphate binding (P-) loop; IB,
imatinib binding region; C, catalytic domain; A, activation loop.
The frequency of point mutations according to the resistance type is presented in Table 10.
Point mutations were detected in both types of resistance. The group “other” included
patients with suboptimal molecular response, or patients having discordance between
cytogenetic and molecular responses.
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Table 10. BCR-ABL kinase domain point mutations detected in imatinib resistant patients
according to the resistance type.
Resistance type n No of patients
with mutations
%
Primary, complete 23 10 43
Primary, partial 16 8 50
Secondary 19 10 53
Other 19 4 21
Total 77 32 42
3.3. Other sequence variations detected (V)
Additional sequence variations were observed in seven subjects representing 19% of all
positively tested patients. Two patients had a rare BCR-ABL transcript of intermediate
length fusing the first six BCR exons to ABL exons 2-11 (e6a2 transcript). One patient
expressed the e19a2 fusion transcript type. The other patients represented the most
common e14a2 (b3a2) or e13a2 (b2a2) transcript types. During the analysis of ABL exons
6 to 10, two PCR products of different size were detected after gel electrophoresis in three
patients: one was of the expected size and the other was a smaller one. Separate
sequencing of these products indicated the splicing out of exon 7 sequences (?362-444,
out of frame) in the shorter PCR product. In addition, a deletion in conjunction with a
kinase domain point mutation was detected in two patients: the presence of L248V
induced a splice site to generate an in-frame deletion in ABL exon 4 (?248-274) and
another variant joining BCR sequences  to ABL exon 4 (?27-183, out of frame) in
conjunction with a F317L mutation.
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Discussion
1. Assessing minimal residual disease
1.1. Technical aspects of determining the level of residual disease in CML (I, II)
Quantitative monitoring of minimal residual disease in CML is of the utmost importance
in the course of current therapeutic strategies. The reduction of >3 logarithm units of BCR-
ABL transcript levels within the first 18 months of imatinib treatment is associated with an
extended progression free survival. Increasing levels of BCR-ABL transcripts may indicate
development of imatinib resistance 52, 314. Similarly, residual BCR-ABL transcripts
detected at low level after alloHSCT do not necessarily indicate forthcoming relapse,
whereas higher levels of BCR-ABL are more likely to confer a risk of disease recurrence
315-316. Since different techniques used for assessing MRD status measure different
variables, i.e. quantitative expression of BCR-ABL transcripts on a molecular level or
percentage of Ph positive mitotic cells on cytogenetic level, it is necessary to evaluate the
concordance of these methods on simultaneously taken samples.
Bone marrow metaphase FISH with high mitotic index and RQ-PCR assays analyzed
from simultaneously taken bone marrow or peripheral blood samples had a good
correlation. Especially FISH and RQ-PCR tests both performed on bone marrow samples
correlated particularly well (rS=0.91, p<0.001). The greater sensitivity of RQ-PCR was
evident in approximately 40% of samples, in which FISH indicated CCyR but which were
nevertheless  MRD  positive  when  studied  with  bone  marrow  or  blood  RQ-PCR.  The
median BCR-ABL reduction in these samples was 3 logarithm units, irrespective of the
RQ-PCR sample type. Significant correlation between bone marrow and peripheral blood
analyses, as well as the superiority of RQ-PCR in detecting low level MRD, has also been
reported by others 181-182, 317.
The selection of reference genes in RQ-PCR assays has varied widely in different
studies. Recent recommendations for harmonizing the methodology used for monitoring
residual disease in CML regarded three genes as valid for normalizing the RQ-PCR data,
namely ABL, BCR and GUS 191. Although ABL was proposed to be used as a calibrator in
RQ-PCR assays by the EAC program 185, quantitative monitoring of CML is not
straightforward with this reference gene. The primers for ABL also amplify BCR-ABL,
thus preventing the meaningful determination of high BCR-ABL/ABL ratio at  the time of
diagnosis. In addition, co-amplification of ABL and BCR-ABL at higher levels of residual
disease (>10%) affect the linearity of the RQ-PCR assay. In Study I, the GUS was chosen
as the reference gene, as it can be used for more accurate determination of diagnostic
transcript ratio. A median baseline BCR-ABL/GUS ratio  can  also  be  obtained  from  the
pretreatment samples and used in a similar way in evaluating the molecular response as
the median BCR-ABL/BCR baseline value was used in the IRIS study 172.
The median baseline BCR-ABL/GUS ratios 35% and 34% consisted of 27 and 32 pre-
treated peripheral blood and bone marrow samples, respectively. The median ratios were
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clearly higher than the reported EAC median values obtained from a slightly lower
number of diagnostic samples (22% from 14 peripheral blood and 12% from 15 bone
marrow samples) 184.  Therefore,  it  is  important  that  the  median  baseline BCR-ABL/GUS
ratio for inter-laboratory and intra-laboratory use is based on a sufficiently large number
of patients.
RQ-PCR standardization and conversion of the results to International Scale
The most sensitive techniques used quantitative monitoring of minimal residual disease in
CML are RQ-PCR methods most often measuring the quantity of BCR-ABL mRNA in the
follow-up samples. However, the RQ-PCR methodologies and choice of reference genes
vary between laboratories. This complicates the comparison of results obtained from
different laboratories. Therefore, the published recommendations on performing RQ-PCR
directed at world-wide standardization of the technique are of great importance 190-191.
Due to current unavailability of commercial standardization assays the International
Scale (IS) has been established by studying samples obtained from a reference laboratory
already applying the IS and determining a conversion factor that converts the laboratory-
specific  data  into  the  same  scale  In  Study  I,  another  kind  of  approach  was  used  in
converting the data into the IS. Since the median baseline value for e.g. peripheral blood
samples was 35% indicating 100% in the IS, the major molecular response corresponding
3-log-reduction of BCR-ABL transcript levels would be 0.035%, indicating 0.01% in the
IS. This produced a conversion factor of 2.864 for peripheral blood samples. This method
also enabled to predict the percentage of Ph chromosome positive cells in concurrent
metaphase FISH assay on the basis of RQ-PCR result on the IS. The reference laboratory-
based approach was also applied in this study, producing a preliminary conversion factor
of 1.8446. The difference between these two conversion factors may be due to different
leukocyte fractions used as the RNA source, namely mononuclear cells in the patient
samples and total leukocytes in standardization samples obtained from the reference
laboratory. The methods used for RNA isolation were also different. These both factors
may have an effect on the sensitivity of the RQ-PCR assay. In addition, the
standardization samples consisted of dilutions from only three CML patients. If these
patients had constant differences in the expression of ABL, BCR or GUS, this it may have
affected the conversion factors between different reference genes.
Metaphase FISH in defining the level of minimal residual disease
Molecular cytogenetic (FISH) follow-up analyses are also efficient in detecting residual
cells during tyrosine kinase inhibitor treatment or after alloHSCT. Even though the
sensitivity of the analysis does not reach to the level of RQ-PCR assays, high mitotic
index metaphase FISH still has some advantages. Quantitative molecular follow-up
studies are not always possible for patients with rare BCR-ABL transcript types in routine
diagnostic laboratories whereas metaphase FISH provides a comprehensive way of
monitoring the disease burden irrespective of the transcript – or translocation type.
Therefore, a close collaboration between the cytogenetic and molecular genetic
laboratories is warranted before diagnosing a patient as BCR-ABL negative. The detection
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of hybridization signals on actual chromosomes enables a morphological analysis of the
metaphase chromosomes. The method does not cause false positive results and also allows
performing karyotype analysis and detecting additional chromosome aberrations referring
to clonal evolution 318. When cytogenetic response is evaluated only on a standard
chromosome analysis of 20 metaphases, it statistically excludes a level of 14% residual
disease (“mosaicism”) with 95% confidence, whereas high mitotic index metaphase FISH
analysis of 1000 metaphases excludes 0.3% of residual disease with the same confidence
interval 177. Therefore the conclusion of complete cytogenetic response determined with
conventional karyotyping may include a significant degree of residual cells. In Studies I
and II the median number of analyzed metaphase cells for MRD setting was 792 and 996,
respectively, thus excluding the mosaicism present at frequency of <1%.
Metaphase FISH, as well as conventional karyotyping, requires dividing cells and
therefore a bone marrow aspirate as a sample for analysis. Peripheral blood sampling
would provide a much less invasive method of assessing the disease burden, but the lack
of  mitotic  cells  does  not  allow  extensive  analyses  at  chromosomal  level.  In  shortage  of
mitotic cells interphase nuclei may also be analyzed with FISH using locus-specific
probes. Correlation of interphase FISH analyses to chromosomal studies has been
evaluated in various works with varying results. When studying samples taken from
patients treated with conventional regimens, the correlation has been very good, but this is
most likely due to higher frequency of BCR-ABL positive cells in the samples 319-320. The
reported correlation of interphase analytics to bone marrow cytogenetics in imatinib
treated patients has been poorer even when using the same sample source (rS 0.40,
p<0.0001) 182. Likewise, peripheral blood interphase FISH compared to bone marrow
cytogenetics had a weak correlation (r 0.64, p=0.013) in imatinib treated patient
population with major discrepancies in several cases. The correlation got better by
analyzing flow sorted peripheral blood neutrophils, but the analysis still produced
discrepant results in some patients 321. In all, the FISH analysis of interphase cells
especially in imatinib treated patient samples is not without problems and the detection of
low level Ph positivity is dependent on the probe type, the cut-off level of false positive
findings used in the laboratory and naturally, the expertise of the analyzer.
1.2. Detection of minimal residual disease from a clinical point of view (I, II)
The monitoring of treatment response in CML needs quantitative and sensitive techniques
for evaluation of low level residual disease. Metaphase FISH analyses require a bone
marrow aspirate as the sample, which is an invasive procedure. In Study I the correlation
between peripheral blood and bone marrow samples in defining the BCR-ABL transcript
levels was good, which also has been observed in other studies 181-182. These findings
favor peripheral blood as the sample of choice in MRD follow-up studies, since peripheral
blood samples enable easier and also more frequent monitoring of MRD by RQ-PCR.
Overall in Study I, the residual BCR-ABL transcript levels were very similar in bone
marrow and peripheral blood. However, some patients had a consistent difference between
the blood or bone marrow MRD values in repeated follow-up samples. Some patients had
consistently higher levels of residual disease in peripheral blood than in the bone marrow,
whereas other patients had the opposite situation. The dependence of the transcript level
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on the cell source has been noted earlier 190, but the biological causes remain yet unknown.
However, in some patients this difference may have an effect on the MRD estimates,
which should be taken into account. Additionally, in these patients the follow-up should
preferably be based on one sample type only. Further studies concentrating on this
variation in BCR-ABL transcript levels are warranted, as it may reflect significant
disparities in CML pathobiology between patients.
Due to lack of world-wide use of the IS in reporting the molecular follow-up data, the
comparability of RQ-PCR results between different laboratories is not straightforward. In
the future, this constraint will hopefully not be an issue in MRD studies. As the duration
of imatinib therapy is getting longer, so does the number of patients whom no BCR-ABL
transcripts can any longer be detected with RQ-PCR 215. However, the level of sensitivity
that each RQ-PCR reaction reaches varies from every run to run depending on the quality
of the sample and efficiency of the reverse transcription and the PCR reactions. The actual
existing amount of low level minimal residual disease in RQ-PCR negative samples also
varies due to the factors mentioned above. Therefore, in cases which turn out negative in
molecular follow-up studies the term “complete molecular remission” should be avoided
in order not to draw the conclusion of complete eradication of the disease. The expression
“BCR-ABL transcripts undetectable” describes the biological situation more accurately 82.
The clinical significance of BCR-ABL fusion transcripts or Ph chromosome positive
metaphases after alloHSCT varies, depending on the level and kinetics of residual cells
detected after transplantation. In Study II, most of the patients (68%) had no Ph positive
residual cells detected during the first four months or the entire follow-up time. This is in
contrast to studies in which BCR-ABL transcripts can be detected early after
transplantation in more than half of the patients when studied with more sensitive RQ-
PCR technique 315. In Study II, 19 patients had a cytogenetic relapse within the first year
after alloHSCT. The rising level of MRD was detectable in five of the early MRD positive
cases being below 1% when first detected, but exceeding the level of 1% and turning into
an overt relapse. Like also indicated in other studies, low and falling frequencies of
residual cells are not necessarily a sign of forthcoming relapse, since low level residual
cells may disappear as a result of graft-versus-leukemia effect. Follow-up of MRD
positive patients is however warranted to monitor the kinetics of MRD level 175, 316, 322.
2. The clinical and biological significance of der(9) deletions in CML (III)
The clinical impact of der(9) deletions has changed over the years being when first
detected an adverse prognostic factor and then later turning into a “warning sign” with so
far unclear significance during the era of tyrosine kinase inhibitors. In Study III, the
clinical impact of der(9) deletions was evaluated in CML patients after alloHSCT.
Deletions in der(9) were detected in 16% of evaluable patients, which is in line with
previous data 64. At the time of diagnosis, no clinically significant differences were
observed between the study groups. Prior to alloHSCT, patients with deletions tended to
have a lower cytogenetic response rate to drug therapy containing interferon-alpha,
probably reflecting the poorer outcome of these patients with conventional CML therapy.
After alloHSCT with a median follow-up time of more than two years, the relapse rate,
overall and leukemia-free survival and transplant-related mortality were similar in patients
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with and without deletions. Previously, in a smaller cohort, the relapse rate after alloHSCT
was higher in patients with deletions than in patients without deletions. However, the rate
of relapse in the non-deleted patients was exceptionally low (4%) indicating a potential
uneven distribution of prognostic variables or too short a follow-up time 76.
Biological significance of der(9) deletions
Several mechanisms behind the worse prognosis in der(9) deletion cases to conventional
therapies have been proposed. Deletions can result in a formation of new fusion genes, but
due to the wide heterogeneity of the localization of the breakpoints this hypothesis seems
unlikely. Der(9) deletion results in a loss of the reciprocal ABL-BCR fusion gene formed
in the translocation. The lack of ABL-BCR and presence of der(9) deletion are still not
concordant, as 65% of the ABL-BCR non-expressing patient do not have a der(9) deletion
detectable by FISH 323. When combined with the clinical data, the ABL-BCR expression is
not correlated with reduced survival or shorter duration of chronic phase 323-324. It is
possible that the ABL-BCR protein modulates the activity of the BCR-ABL protein, but
the data on stable ABL-BCR expression at the protein level are yet lacking 64, 325.
Chromosomal deletions can abolish tumor suppressor genes, which when inactivated
due to “the second hit” in the non-deleted allele, change the cells malignant.
Haploinsufficiency, a situation in which the reduction of gene dosage causes an aberrant
phenotype, is another mechanism contributing to tumor formation. The biological
consequence of der(9) deletions can be either of these. The chromosomal regions affected
in der(9) deletions are gene rich and the critical target genes are yet to be identified 64.
Der(9) deletions can also reflect general genomic instability causing predisposition of
accumulating additional genetic changes in the leukemic cell population. The deletions
could then act as a surrogate marker for additional genomic deletions. The biological
effect of the deletions though yet unknown are most probably highly complex, potentially
involving several of the mechanisms presented above 69.
The frequency of der(9) deletions in patients with variant Ph translocation
Deletions in der(9) have previously been detected with greater frequency (40%) in CML
patients with variant Ph translocations 50, 63. This has been considered as an explanation
for the conflicting results obtained from survival analyses 50.  However,  in  Study  III,  no
deletions in patients with variant Ph translocations were observed. The lack of variant Ph
translocations in patients with deletions in the study material can be a chance finding, as
the expected number of such patients was only four. By the beginning of March 2008 a
total of 19 CML patients with variant translocation are evaluable regarding their der(9)
deletion status. Only three patients (16%) have been diagnosed with a deletion, others
having a signal pattern characteristic of a variant translocation without a deletion. Thus the
frequency of der(9) deletions in variant translocations appears to be similar to the standard
translocations in Finnish CML patients. The reason to this difference is unknown.
However, the small number of deletions could reflect a real and intriguing difference in
the genetic background of CML.
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The impact of der(9) deletions during the era of tyrosine kinase inhibitors
The advent of first and second generation tyrosine kinase inhibitors has revolutionized
the treatment of CML and also affected the impact of der(9) deletions as an adverse
prognostic marker. Due to somewhat diverse results on the deletion status during
treatment with tyrosine kinase inhibitors, as reviewed in chapter 3.4.2., more studies are
needed to resolve the current significance of der(9) deletions. Unless otherwise indicated,
the deletion status should therefore be determined consistently as a part of routine
diagnostics.
3. Prognostic factors related to imatinib treatment
3.1. Bone marrow lymphocytosis as a predictive marker for optimal response (IV)
Imatinib treatment induces rapid hematologic responses in nearly all patients. However, a
proportion of these patients fail to achieve any kind of cytogenetic response. The reason
for this type of cytogenetic resistance is unknown. Similarly, it is not known why among
patients having a favorable response to imatinib therapy, some achieve the MMR within
optimal time, indicating long-term progression free survival, as others do not. One
potential factor contributing to the optimal treatment response could be the patient’s
immune system, participating in the eradication of leukemic cells. The findings of Study
IV could support the idea of immune response in the clearance of leukemic clone, since
lymphocytes are the principal effector cells of the immune system.
Studies assessing the effects of imatinib on the immune system have resulted in
contrasting findings. Some studies found imatinib an immunostimulating drug, whereas
other studies suggested that imatinib has suppressive effects on immune system.
Activating effects of imatinib have been observed through a significant rise in the
frequency of interferon-gamma producing T cells after a median of three-month imatinib
therapy. In addition, vaccination studies with a p210-derived peptide in combination with
imatinib have shown no impairment of specific anti-leukemia T cell responses and thereby
vaccine efficacy. Immunosuppressive effects of imatinib have been observed in other
studies. Inhibition of the proliferation of activated T cells after addition of imatinib has
been described. Negative impact of imatinib on the formation of dendritic cells and
incomplete recovery of these cells in peripheral blood has also been proposed, as reviewed
by Mohty et al 2005 45. Based on these findings, the immunological effects of imatinib
appear to be extremely diverse. Therefore more studies are warranted to clarify the
implications of imatinib and immune system on tumor elimination.
The bone marrow lymphocytosis detected in Study IV was superior in predicting
cytogenetic and molecular genetic responses compared to conventional prognostic
markers. When the appearance of bone marrow lymphocytosis was combined with
cytogenetic data, the combination of lymphocytosis and major cytogenetic response at
three months of imatinib therapy predicted a MMR at 18 months of therapy with a positive
predictive value of 100%. The appearance of bone marrow lymphocytosis thus proved to
be a novel, powerful predictive factor for an optimal response to imatinib treatment. When
put together with cytogenetic data, suboptimally or poorly responding patients could be
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distinguished as early as three months of therapy. Due to a limited number of patients in
this study these findings need to be confirmed in a larger setting. However, the evaluation
of bone marrow lymphocyte count could be included in the evaluation of early response in
imatinib treated patients.
3.2. BCR-ABL kinase domain mutations (V)
Point mutations in the region encoding the BCR-ABL kinase domain are one important
mechanism of resistance to imatinib or other tyrosine kinase inhibitor treatment. Most of
the mutations conferring imatinib resistance may be overcome by a second generation
inhibitor, such as dasatinib or nilotinib. However, the “gatekeeper” mutation, T315I,
causes  resistance  to  all  inhibitors  currently  available  and  is  therefore  problematic  in
clinical practice. The lack of T315I in this study was surprising, as T315I is one of the
most common single mutations detected in previous studies 228-229, 232. More recently, the
T315I substitution has been shown to count for approximately 20% of imatinib resistant
cases 326. The reason for variable incidence of T315I in different reports may be related to
study design, or differences in genetic background of the study population 327.
In previous reports, mutations were less frequently regarded as a causative factor for
primary resistance and other mechanisms of resistance are regarded more common 229, 328.
In contrast, results in the Study V indicate that the kinase domain mutations were also
significant for resistance in patients who are refractory upfront to imatinib therapy. This
may be related to the length of disease history, since many of the patients analyzed were in
late  chronic  phase  or  in  advanced  phase  at  the  time of  starting  imatinib.  Putatively,  cell
clones harboring pre-existent mutants with high proliferative potential were selected upon
imatinib treatment in these subjects, rapidly resulting in a significant tumor load which
upon cytogenetic evaluation at six months might be interpreted as primary resistance
rather than a rapid development of a pre-existing clone.
The impact of BCR-ABL deletions and alternative splicing on imatinib resistance
remains to be determined. Alternative splicing of BCR-ABL transcripts has also been
reported by others and it seems to be relatively common phenomenon in CML 329-331.
Many of the deletions and splice variants break the open reading frame of the gene and
result in a premature termination of protein synthesis. P-loop deletion mutants that
preserve the reading frame, like ?248-274 in conjunction with L248V point mutation, are
also catalytically inactive. This was hypothesized as having a dominant –negative effect
on  the  oncogenic  potential  of  the  mutant  and  native  BCR-ABL  dimers.  However,  the
growth factor independence and activation of signaling was retained in cells coexpressing
deleted and native forms of BCR-ABL. But when treated with imatinib, the cells had an
increased sensitivity to imatinib, which refers to a dominant-negative effect with respect to
drug sensitivity 331. Therefore the deletions and alternative splicing appear unlikely to be
the causative factor for resistance. However, more studies are needed to clarify the
significance of deletions and exon splicing in context of resistance, but also in the biology
of CML.
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Mutation analyses: when and how?
Appearance  of  primary  or  secondary  resistance  as  defined  in  the  present  work  is  a  clear
indication for mutation testing. First signs of secondary resistance may be detected by a
serial increase in MRD as detected by BCR-ABL RQ-PCR from peripheral blood 332.  A
confirmed half-log increase or a rise of more than two-fold in BCR-ABL RQ-PCR levels
have  also  been  proposed  as  indicators  for  higher  risk  of  relapse  and  kinase  domain
mutations 314 333. In previous studies, no precise definitions for primary resistance have
been presented. Our definition of primary resistance as used in Study V appears clinically
useful and can be used as a guideline for selecting patients for mutational analyses.
The methodology used for mutation screening is variable. One of the most often used
method  is  the BCR-ABL fusion specific PCR followed by nested-PCR and direct
sequencing of the region encoding the kinase domain 229, 312. Direct sequencing has a
sensitivity limit of 10-30% which hampers the early detection of resistant clones.
Denaturing high performance liquid chromatography (DHPLC) and pyrosequencing are
more sensitive methods with sensitivity levels of 10-15%, or even below 1%.
Pyrosequencing also enables the quantification of the mutated clone 243, 334-335.
Allele specific oligonucleotide (ASO-) or amplification refractory mutation system
(ARMS-) based PCR assays are also highly sensitive techniques for mutation detection.
They are useful mutation-specific methods for detecting low level mutations or in
quantitative follow-up of a previously detected mutated clone 242, 336. Assays designed for
follow-up studies may be as sensitive as detecting 0.1% of the mutated clone 336.
However, when the mutation causing resistance is unknown, the screening technique
should be unbiased, detecting all kinds of sequence variations.
In addition to mutation screening, both conventional karyotyping and BCR-ABL FISH
should be performed at the time of resistance. These assays detect cytogenetic clonal
evolution and BCR-ABL amplification which are also mechanisms for drug resistance.
4. Future prospects
The detailed molecular knowledge on targeted therapies and the emerging resistance
against these drugs has increased over the years and provided new tools and strategies for
handling clinical situations associated with drug resistance. However, inhibition of the
multidrug-resistant  T315I  mutation  positive  BCR-ABL  remains  one  of  the  main
challenges. New promising agents that are either targeted against BCR-ABL or are
activating other, suppressed proteins in advanced phases of the disease are in clinical
stages of development 301, 337-338. New treatment options will also create a need for novel
prognostic factors assessing and predicting treatment response, such as bone marrow
lymphocytosis during imatinib treatment. Pharmacodynamic assessments, such as
determination of the in vitro and in vivo activity of new drugs against BCR-ABL isoforms
will have increasing importance, and they provide important endpoint data for
combinations of various treatment strategies, such as tyrosine kinase inhibitors, immune
therapy and drugs targeting epigenetic alterations 339-340.
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The need for predictive factors for drug resistance is also a subject for further studies.
The  determination  of  baseline  mutations  or  other  mechanisms  of  resistance  could  be
valuable in choosing the most efficient treatment for the patients. In de novo Ph
chromosome positive ALL, pre-existing kinase domain mutations are detected at low level
in  at  least  40%  of  the  newly  diagnosed  patients  with  no  exposure  to  imatinib  and  these
mutations were the ones that were responsible for relapse of the disease 341. This
emphasizes the need of highly sensitive techniques for mutation detection and monitoring
242, 336, 342 and also the necessity to understand the determinants of growth advantage of
both mutated and unmutated leukemic clones over healthy bone marrow cells.
Despite the growing knowledge of new treatments and the discovery of new prognostic
factors, the conventional prognostic variables are remarkably tenable. The Sokal score,
developed in the 1980’s for patients treated with single-agent chemotherapy (most
commonly busulfan), is valid for imatinib treated patients as well, and predicts lower rates
of CCyR and higher estimated risk of disease progression for Sokal high risk patients at
five years of treatment 52. Similarly, conventional karyotyping with standard G-banding
has been sufficient in illustrating 97% progression free survival at five years of imatinib
therapy 52. Therefore, the advent of new prognostic factors does not necessarily render
older variables obsolete, but complement the assessment of prognosis of CML patients.
The efficacy and good correlation of RQ-PCR and metaphase FISH methods as well as
the concordance of bone marrow and peripheral blood samples in detecting MRD have
been proven in many reports. This makes the utilization of peripheral blood as the primary
sample source for the RQ-PCR follow-up analyses reasonable. However, the situation is
not that straightforward in all patients, as some individuals exhibit a marked discordance
between  RQ-PCR  and  metaphase  FISH  -  or  conventional  cytogenetic  -  studies.  For
example, in one chronic phase, low Sokal-risk CML patient, the 18-month follow-up
sample showed CCyR by FISH analysis from 1000 metaphase cells, whereas
simultaneously taken peripheral blood or bone marrow RQ-PCR assays indicate less than
1-log reduction from the diagnostic baseline referring to suboptimal response. The
biological mechanisms and clinical significance of these ambiguous cases is subject for
further studies.
Although the efficacy of currently used tyrosine kinase inhibitors has been documented
on  several  occasions,  they  all  have  the  same  limitation:  leukemic  quiescent  (out  of  cell
cycle) stem cell compartment is insensitive to these inhibitors 343-345.  This  has  also  been
observed in clinical setting as patients relapse after imatinib discontinuation, although
BCR-ABL has been undetectable by PCR in samples prior to discontinuation 346.
However, this is not the case in all patients, possibly reflecting long-term benefit of earlier
therapies (i.e. interferon) or other heterogeneity among the patients. Nevertheless, the
cessation of imatinib treatment is not recommended at the present time 42. New drugs
targeting cancer stem cells are being developed constantly. One such agent, BMS-214662,
has recently been reported as inducing apoptosis in leukemic stem cells while sparing
normal stem cells 347.
The aim of current and upcoming prognostic markers will remain the same: aid in the
selection of right therapies for right patients. In the future, some CML patients may be
cured with a combination of powerful targeted therapy strategies and accurate laboratory
tools measuring their effect.
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Summary and conclusions
The story of chronic myeloid leukemia describes comprehensively the developmental span
of how the detection of consistent chromosomal abnormality eventually leads to a targeted
drug and its second generation successors used for treating the emerged resistance. CML
is aptly regarded as a model disease for cancer that may have implications for the
development of targeted therapies for other malignancies as well.
This thesis was constructed during the advent of tyrosine kinase inhibitors. Imatinib as
the first generation inhibitor has become the first-line treatment for newly diagnosed CML
patients.  However,  conventional  therapies  such  as  alloHSCT  have  still  a  role  in  the
treatment of CML, although their role as the first-line treatment option has changed. The
emergence of new prognostic factors related to the new regimens, such as the level of
MRD  after  18  months  of  imatinib  therapy,  emphasize  the  importance  of  precise  MRD
analytics even more than before. Sensitive and quantitative methods are a prerequisite for
today’s genetic laboratories performing follow-up studies for CML patients.
The correlations between various techniques monitoring minimal residual disease from
different sources of material were assessed in Study I. Bone marrow metaphase FISH and
RQ-PCR assays performed from bone marrow or peripheral blood mononuclear cells
correlated well with each other. The better sensitivity of RQ-PCR analyses was evident in
approximately 40% of the metaphase FISH negative samples still indicating low level
MRD with RQ-PCR with a median log-reduction of three units. A model or converting the
data into the International Scale was presented, yielding the conversion factor of 2.86. In
addition, the data enabled the conversion of bone marrow metaphase FISH results into the
same scale, as well.
The clinical and practical significance of bone marrow metaphase FISH in the follow-
up analyses of CML patients after alloHSCT was evaluated in Study II.  Ph chromosome
positive cells were observed in 32% of the patients during the entire follow-up time. A
total of 12% of the patients showed low-level (<1% of residual cells) and falling MRD,
whereas 19% had a serial rise in MRD level exceeding 1% or had at once more than 1% of
Ph chromosome positive cells when detected for the first time. In all, no spontaneous
eradication of residual cells was detected when the frequency of Ph positive cells
exceeded 1% at any time during the follow-up. The threshold of 1% has practical value in
metaphase FISH analytics but its clinical significance needs to be validated in larger trials.
The impact of derivative chromosome 9 deletions on the disease course and treatment
response after alloHSCT was determined in Study III. Deletions were found in 15% of all
patients, which is in line with previously published reports. Curiously, in contrast to other
publications, no deletions were observed in patients with variant translocations. In the
updated analyses made by the end of February 2008, the frequency of der(9)deletions
seems to be similar to standard translocations in Finnish CML patients, as only three out
of 19 evaluable patients with a variant translocation have been diagnosed as having a
der(9) deletion (16%). The frequency is still clearly lower than expected in patients with
variant translocations and it may reflect some kind of difference in the genetic background
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of the disease in Finnish CML patients. Prior to transplantation the patients with deletions
tended to have a poorer cytogenetic response to an interferon-alpha -containing therapy,
though the finding was not statistically significant. After transplantation, no difference in
the total relapse rate during follow-up was observed in patients with or without deletions.
Neither did the Kaplan-Meyer outcome estimates for overall survival, transplant-related
mortality, leukemia-free survival and relapse-free time show any difference between these
patient groups. Therefore, during conventional treatment regimens, the der(9) status could
be an important criterion in conjunction with other prognostic factors, such as the EBMT
score, when considering allogeneic transplantation. However, the prognostic significance
of der(9) deletions in the era of tyrosine kinase inhibitors is not clear, requiring further
studies in this field.
Factors associated with favorable or unfavorable response to imatinib treatment were
assessed in Studies IV and V. The appearance of bone marrow lymphocytosis during
imatinib therapy (IV) proved to be a powerful predictive factor for optimal treatment
response. When combined with the results of conventional cytogenetics, the patients with
suboptimal  or  failed  response  to  imatinib  could  be  distinguished  as  early  as  at  three
months of therapy. Similarly, bone marrow lymphocytosis and major cytogenetic response
at three months predicted prognostically important major molecular response at 18 months
of imatinib treatment. The validation of these findings with a larger patient material is
warranted. However, the evaluation of bone marrow lymphocyte count could easily be
included in the evaluation of early response.
Acquired mutations in the BCR-ABL kinase domain are unfavorable factors associated
with imatinib treatment (V). The patient material consisted of CML patients experiencing
either primary or secondary resistance against imatinib treatment. All the point mutations
detected in the kinase domain were previously reported ones, known to confer imatinib
resistance. However, in contrast to many other studies, no multi-drug resistant T315I
mutations were found. In addition, other sequence variants besides point mutations,
namely deletions and exon splicing, were found. Most of the deletion mutants were out-of
frame mutations that resulted in a premature stop codon in the BCR-ABL transcript. The
clinical significance of these deletion mutants remains to be determined. In all, mutation
testing should be done predominantly from patients fulfilling criteria for primary or
secondary resistance.
This thesis has provided information on novel prognostic markers in Finnish and
Norwegian CML patients and also has indicated some special features observed in this
patient group. In addition, a new marker predicting optimal response to imatinib treatment
was described. Many of these observations are clinically applicable and also provide basis
for further research work with the aim of developing curative drug therapy strategies for
CML.
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